INCLUDES:

AUSTRALIAN DERMATOLOGY NURSES’ ASSOCIATION 16TH NATIONAL CONFERENCE SATURDAY 6 MAY AND SUNDAY 7 MAY 2017

50TH ANNUAL SCIENTIFIC MEETING INTERNATIONAL CONVENTION CENTRE SYDNEY, DARLING HARBOUR, NEW SOUTH WALES, AUSTRALIA SATURDAY 6 MAY TO TUESDAY 9 MAY 2017

www.acdasm2017.com PROGRAM WELCOME FROM THE PRESIDENT CELEBRATING Celebrating College’s Welcome to Sydney, New South Wales for the 50th Annual 1967-2017 Scientific Meeting of the Australasian College of 50 years and 50 meetings! Dermatologists.

The local organising committee this year was headed by Associate Professor Samuel Zagarella as Convenor, Dr Ian Hamann and Dr Monisha Gupta as Co-Convenors, and supported by the College’s Scientific Meetings Steering Committee. The New South Wales Faculty welcomes Fellows, trainees, students and other medical practitioners to the meeting.

I am excited to welcome our overseas speakers: Professor Alex Anstey, Honorary Professor of Dermatology at Cardiff University, Advisory Professor of Dermatology to Jaio Tong University, Shanghai, China and Editor of the British Journal of Dermatology (BJD), Bangor, North Wales. Dr Ashfaq Marghoob, Director, Memorial Sloan Kettering’s Regional Skin Cancer Clinic, Hauppauge, New York, United States of America. Professor Ronald Rapini, Chernosky Distinguished Professor and Chair of the Department of Dermatology and Professor of Pathology, University of Texas Medical and Chair of the Department of Dermatology and Professor of Pathology, MD Anderson Cancer Center, Texas, United States of America. Dr Scott Fosko, Consultant and Chair of the Department of Dermatology, Mayo Clinic, Florida, Adjunct Professor, Department of Dermatology and Saint Louis University Center for Outcomes Research, Saint Louis University School of Medicine, Missouri, United States of America.

The meeting has been strongly supported by the pharmaceutical and allied health industries as sponsors and trade exhibitors. I invite all delegates to visit the displays in the trade exhibition, to meet the industry representatives and to learn about new developments in products and services. It is with the very generous support of our sponsors and exhibitors that the College is able to hold a meeting of this size and quality.

I hope you all find this meeting a worthwhile and enjoyable experience.

Associate Professor Christopher Baker, FACD

2 BOARD OF DIRECTORS 2016/2017

Associate Professor Christopher Baker______President Dr Andrew Miller______President-Elect Dr Andrew Satchell______Honorary Secretary Dr Adrian Lim______Dean of Education Associate Professor Saxon Smith______Elected Director (NSW) Dr Alan Donnelly______Elected Director (WA) Dr Robert I. Kelly______Elected Director (VIC) Dr Anne Lewis______Elected Director (SA) Dr Michael Pitney______Elected Director (QLD)

MEMBERS OF THE COLLEGE

Dr K. Engeti A/Prof. S. Kossard Dr H. Fallah Dr J.F.C. Krivanek A/Prof. P. Fernandez-Peñas Dr J.M. Kuchel A/Prof. G. Fischer, AM Dr A. Kumar NEW SOUTH WALES FACULTY Dr J. Fisher Dr A. Kurien Dr N.S. Agar Dr B. Florance, RFD, RD* Dr A-M. Kurzydlo Dr P. Alexander Dr P.C. Frederiksen Dr E. Lamrock Dr F.E. Anderson* Dr P.A. Freeman Dr W.A. Land, AM, RFD, AE Dr R.P. Armati Dr S. Freeman Dr M.M. Lane-Brown Dr P. Artemi Dr J. Frew Dr K.H. Le Dr N. Aspres Prof. K. Georgouras, OAM Dr M-L. Lee Dr S. Bakis-Petsoglou Dr D. Gillam (deceased 6 Dr M-S. Lee Dr M. Bannister October 2016) Dr M. Lee Emer. Prof. R.St.C. Barnetson Dr R. Gillespie Dr P.A. Lee Dr L.D. Bear Dr T.K. Gilmour Dr S.H. Lee Dr G. Becker Dr G. Gottschalk Cl. Prof. S. Lee, AM Dr P. Brown Dr E. Gow Dr J.L. Le Guay Dr G.D. Cains Dr I. Grigoris Dr M. Leibowitz Dr H. Chan Dr K. Gudmundsen Dr L.J. Leow Dr J.C. Chapman Dr P. Guitera Dr J. Lewis Dr P.G. Chee Dr M. Gupta Dr M. Li Dr K. Chen Dr R. Gupta Dr A. Lim Dr J.Y.J. Choi Dr I.D. Hamann Dr P. Lim Dr E.Y.Y. Chow Dr R.S. Hannaford Dr T.K. Lipscombe Dr R. Cocciolone Dr R. Harvey Dr M. Llewellyn Cl. A/Prof. C.A. Commens Dr M.F. Healsmith Dr E. Lobel Dr D.K. Cook Dr S. Heiman Dr M.S. Loghdey Dr N. Cook Dr K.K-L. Ho A/Prof. P.M. Lowe Prof. A.J. Cooper, OAM Dr P. Hogan Dr J. Mackay Dr G. Cottee Dr D. Holt Dr A.R. Mackenzie-Wood Dr A.E. Cronin* Dr E. Hong Dr L. Martin Dr K.A. Crotty Dr R. Howes Dr J. Matulich Prof. D.L. Damian Dr M.J. Hunt Dr I.D. McCrossin Dr D.E. Davies Dr N.T. Huynh Dr R.R.A. McDonald Dr E. Dawes-Higgs Dr F. Isaacs Dr S. McDonald Dr J.W. de Launey Dr N, Jang Dr B. McGaw* Dr W.E. de Launey Dr D. Jenkins Dr C. McKay Dr R.W. Denisenko Dr M. Jones-Caballero Dr M. McRae Dr S. de Zwaan Dr S. Kalouche Dr A.C. Miller Dr E. Doherty Dr C.R. Kearney Dr A. Ming Dr S. Donoghue Dr S. Khurana Dr G. Moreno Bonilla Dr C.J. Drummond Dr A. Kline Dr C. Morrow Dr K.J. Dunlop Dr C. Koh Dr A.St.L. Moss Dr P.K. Dwyer Dr J. Konya Dr E. Mullan

3 Prof. D. Murrell Dr G.C. Watt Dr M.W. Harley Dr S.Y. Ng Dr A. Wegman Dr A. Herat Dr R.T.D. Nguyen Dr P.A. Weller Dr R.J. Hills Dr A. O’Neill Dr J. Wells Dr G.J. Holmes Dr C.S-C. Ong Prof. W. Weninger Dr B. Jones Dr V. Paddon Dr L. Wheeler Dr L.J. Kelly* SOUTH AUSTRALIAN Dr B.K-C. Pang Dr H.A.D. White, AM, RFD A/Prof. K. Khostrotehrani FACULTY A/Prof. K. Parsi Dr M. Whitfeld Dr Y.J. Kim Dr S. Anabarasu Dr A. Patel Dr E. Willsteed Dr S. Kumar Dr P. Armenores A/Prof. R.D. Paver Dr N. Wines Dr Y.N. Lau Dr S. Ball Dr R.D. Peek Dr R. Wittal Dr C.T. Lee Dr C. Black Dr T.A. Phan Dr D.Y-S. Wong Dr K-C. Lee Dr M. Black Dr T.S.C. Poon Dr D.A. Wong Dr Y. Lee Dr G. Casey Dr E. Pritchard Dr K.C-W. Wong Dr D.F. Leslie Dr E. Christou Dr V. Pua Dr L-C.F. Wong Dr D. Lim Dr R.M. Czechowicz Dr W. Regan, AM Dr G. Wood, AM Dr K.R. Lun Dr C.M. Duguid Dr J.P. Relic Dr J. Woods Dr S. Manoharan Dr E. Ellis Emer. Prof. S.W. Richards Dr E. Yiasemides Dr I. McColl Dr L. Gordon Dr C.A. Riordan Dr J. Yip Dr P.L. McLaran Dr N.L. Grieve Dr J. Robinson Dr I.R. Younger Dr E. McMeniman Dr M.J.A. Hanna Dr M. Rogers A/Prof. S.S. Zagarella Dr C.H. Mercer Dr E. Haverhoek Dr R.H. Rosen Dr P.M. Millar Dr D.C. Hill Dr D. Rubel Dr R.MacD. Miller A/Prof. S.C. Huilgol Dr W.J. Ryman Dr A.B. Mirza Dr S. Khoury Dr L. Sagi Dr J.B. Muir Dr K.J. Koh Dr R.M. Salmon Dr A.J.D. Mulholland Dr Y-C. Lee Dr A.C. Satchell QUEENSLAND FACULTY Dr R.R. Noakes Dr A.E. Lewis Dr C.A. Saywell Dr C.D.Y. Adib Dr M.A. Oziemski Dr D. Long Dr L. Saywell Dr M.L. Andrews Dr S.M. Ozluer Dr H. Ly Dr D. Sebaratnam Dr J.C. Auld Emer. Prof. J.A. Pagliaro Dr R. Manifold Dr A.C.Y. See Dr H. Avery Dr C. Petherbridge* Dr G. Marshman Dr J-A. See Dr S. Baghaei Dr M.J. Pitney Dr J. Menz Dr J.F. Shannon Dr L. Banney Dr W.W. Pruim Dr S.C. Murray A/Prof. S.P. Shumack, OAM Dr K.E. Behne Dr S. Reid Dr K. Newland Dr S.E. Sinclair Dr I. Browne Dr I.M. Robertson Dr J. Nicolson Dr J.R.A. Sippe Dr D. Burdon-Jones Dr K.H. Rodins Dr V.F. O’Brien Dr G. Sivapirabu Dr G.J. Butler Dr C. Sander Dr C.G-G. Ooi Dr A. Smth Dr J.L. Byth Dr M.S. Saywell Dr C.J. Parker Cl. A/Prof. S. Smith Dr B. Carew A/Prof. H. Schaider Dr A.L. Pearce Dr S.K. Sohal Dr M. Carroll Dr S. Scuderi Dr C. Reid Cl. A/Prof. D.G. Stanford Dr T. Casey Dr M.P. Sharkey Dr C. Ross Dr K.M. Stapleton Dr J.E.D. Chick Dr V.L. Shepherd Dr E. Ryan Dr E. Starritt Dr K-Y. Choong A/Prof. G.M. Siller Dr P.A. Selva-Nayagam Dr A. Steele-Smith Dr D. Coates Dr P.R. Sinclair Dr K. Shirato Dr J. Steele-Smith* Dr J.G. Coates Dr R.J. Sinclair Dr S.K. Sidhu Dr R.B.H. Stephens Dr N.J. Collins Prof. H.P. Soyer Dr I.J. Simmons Dr M. Stewart Dr B-I. Cominos Dr L.J. Spelman Dr D. Tilakaratne Dr N. Stewart Dr S. Congdon Dr G.J. Stephenson Dr C.J. Tyson Dr H.M. Studniberg Dr S.L. Conias Dr D. Surjana Dr S. Vaidya Dr J.R. Sullivan Dr C. Curchin Dr P. Teng Dr P.C. Walker Dr M.C. Symons Dr T.A. Darben Dr S. Tritton Dr L.J. Warren Dr M. Tam Dr S. Davidson Dr S. Tucker Dr F.J. Tefany Dr B.J. De’Ambrosis Dr Y.Y. Vun Dr K.E. Thai Dr K. DeAmbrosis Dr G.H. Wagner Dr C.H.F. Thoo Dr R.M. De Voss Dr S.D. Waite Dr N. Todes-Taylor Dr A.J. Dore Dr M. Warren Dr A. Tomizawa Dr C.F. Faulkner Dr S. Webber VICTORIAN FACULTY Dr A. Varol Dr D.B. Francis Dr J.W. Wells Dr A.N.R. Amerasinghe Dr S. Venugopal Dr M.G. Freeman Dr L. Wheller Dr K. Armour Dr E. Waine Dr G. Frost Dr P.R. Wilson A/Prof. C.S. Baker Dr B. Wallace Dr D. Gaffney Dr J.K-H. Wu Dr J. Banky Dr R. Walther Dr Z.S. Gaspar Dr S.A. Yong-Gee Dr P.S. Bekhor A/Prof. O. Wargon, OAM Dr R. Gild Dr C. Yoong Dr P.A. Berger Dr R. Watchorn Dr A.M. Godbolt Dr L. Young Dr F. Bhahba Dr A.B. Watson Prof. N. Haass Dr T. Zappala Dr N.R. Bleasel

4 Dr T. Bohl Dr P.J. Lane Prof. R.D. Sinclair Dr K.M. Opie Dr A. Boyapati Dr D. Lanzer A/Prof. M.J. Sladden Dr L.M. Pepall Dr A. Boyce Dr A. Lasocki Dr A. Stavrakoglou Dr C.J. Quirk Dr A. Braue Dr A.Y.L. Lee A/Prof. J.C. Su Dr P.L. Randell Dr B. Breadon Dr M.W-K. Lee Dr B. Swan Dr B. Ricciardo Dr S.K. Brennand Dr S-W. Lim Dr E.H. Taft, AM* Dr J.B. Rohr Dr F.J. Bruce Dr W. Liu Dr M.M. Tam Dr G.M. Sadler Dr J.C. Burford Dr L. Ly Dr B.T. Tan Dr D. Singh Dr J.M. Butler, AM Dr G. Lyons Dr E. Tan Dr G.D. Singh Dr J. Cahill Dr E. Ma Dr B.J. Tate Dr P. Singh Dr A.W. Callan Dr R. Mak Dr D. Tran Dr T.M. Skender-Kalnenas Dr N.J. Callan Dr A.W-Y. Mar Dr A. Tuxen Dr H. Smith Dr J. Cargnello Dr V. Mar Dr E.J.McK. Upjohn Dr P.T. Swarbrick Dr A. Catona Prof. R. Marks, AM Prof. G.A. Varigos Dr Y.J. Tai Dr A.J. Chamberlain Dr D.M. McColl Dr A. Verma Dr C.P. Tait Dr S. Chandra Cl. A/Prof. C.J. McCormack Dr E. Veysey Dr E.B.C. Tan Dr V. Chitreddy Dr C. McDonald Dr R. Vyas Dr G.A. Thom Dr A.H.O. Chong Dr C.J. Meehan Dr F. Y-Y. Watkins Dr J. Tu Dr M. Cicchiello Dr A.C. Michaelides Dr M.R. Webster Cl. A/Prof. C. Vinciullo Dr A.C. Ciconte Dr O. Milne Dr B.M. Welsh Dr J.A. von Nida Dr T.J. Connors Dr M. Mohamed Prof. I. Winship Dr L.M. Wall Dr P.S.J. Cowen Dr E. Mooney Dr K. Wolfowitz Dr S. Weston Dr R.B. Crouch Dr V.A. Morgan Dr A. Wright Dr P.A. Curnow Dr M.L.L. Moyle Dr L-M. Yap Dr M. Darling Dr J. Ng Dr A. Yazdabadi Dr R. De Cruz Dr R. Nguyen Dr J.M. Yeatman Dr R.L.S. Dickinson Dr J. Nicolopoulos Dr L. Yip Dr H. Dinh A/Prof. R. Nixon OVERSEAS Dr C. Dolianitis Dr D.S. Nurse* Dr N. Abbott Dr N.P. Downes Dr T.J. O’Brien Prof. C. Anderson Dr R. Dunn Dr R.J. O’Keefe Dr S. Arnold Dr D. Dyall-Smith Dr M. O‘Loughlin Dr T. Carner Dr S. Eisman Dr J.M. Opie WESTERN AUSTRALIAN Dr E. Finkelstein Dr B.R. Entwisle* Dr D.C. Orchard FACULTY Dr J. Foo Dr P.E. Fergin Dr M. Palmer Dr J. Adamson Dr M. Heng Dr A. Fitzgibbon Dr V. Palmer Dr J.H. Allison* Dr M. Lowes A/Prof. P.A. Foley Dr Y. Pan Dr A. Anderson A/Prof. F. Moloney Dr D. Gan Dr A. Perez De Velasco Dr K. Borchard Dr A. Saracino Dr D.V. Gill Dr E.C-H. Poon Dr R. Brand Prof. W. Sinclair A/Prof. S. Gilmore Dr B. Rajagopalan Dr T. Caccetta Dr F. van der Walt A/Prof. D. Gin Dr D. Rathnayake Dr J.J.S-M. Chan Dr M. Wade Dr M.S.Y. Goh Dr G.J. Rennick Dr P. Cherian A/Prof. G.J. Goodman Dr J. Rhodes Dr H.C. Chua Dr J. Green Dr M.V. Rich Dr C. Clay Dr C. Grills Dr H. Roberts Dr J. Cole Dr S. Gunatheesan Dr S. Robertson Dr B.L. Connor RESIDENT IN NEW Dr S. Gupta Dr M.A. Rodrigues Dr K.J. Dallimore ZEALAND Dr L.R.S. Hale Dr G.L. Ross Dr T.A. Delaney Dr J.D. Adams A/Prof. A.P. Hall Dr A. Rudd Dr A.M. Donnelly Dr L.M. Armstrong* (SA Dr S.C. Harrison Dr R. Ruiz Araujo Dr T.G. Elliott Faculty) Dr M.I. Haskett Dr T.J. Rutherford Dr R. Foster Dr W.J. Burton Dr E. Hiscutt Dr K. Sandhu Dr G. Foxton (NSW Faculty) Dr J. Horton Dr H.L. Saunders Dr H. Gebauer Dr T. Gunson (WA Faculty) A/Prof. Dr A. Howard Dr L.V. Scardamaglia Cl. A/Prof. K. Gebauer Dr M.W. Hursthouse Dr C. Jalilian Dr C.E. Scarff Dr R. Granger (SA Faculty) Dr W.J. Jamieson* Dr C. Schofield Dr A.R. Halbert Dr D. Rowan (deceased 12 March 2017) Dr A.H. Segal Dr W.K. Hedley (SA Faculty) Dr A. Jevtic Dr M. Seith Dr D. Hewitt Dr P.J. Sears Dr A. Jopp-McKay Dr N. Sharma Dr C. Heyes Dr B.C. Turnbull* Dr S. Joseph Dr P. Sharma A/Prof. P. Kumarasinghe (SA Faculty) Dr J.R. Kelly* Dr D.A.R. Shephard Dr D. Lim Dr D.W. Young Prof. J.W. Kelly Dr A. Sheridan Dr G. Masel (VIC Faculty) Dr R.I. Kelly Dr N. Shim Dr G. Moloney * Foundation Members Dr J. Kern Dr P.A. Sinclair Dr W.B. Muston*

5 HONORARY MEMBERS

Cl. Prof. C.L. Goh______Singapore Dr J. Hawk______United Kingdom Prof. P. Mortimer______United Kingdom Prof. E. Tschachler_____ Austria

ASSOCIATE MEMBERS

Dr T.W. Beer______Western Australia Dr C. James______South Australia Dr P. Bullpitt______New South Wales Dr B. Kynaston______Queensland Dr K.C. Chong______Queensland Dr J. Magee______Victoria Dr E.C. Cleary______South Australia Dr S. Mann______New South Wales Dr R. Crouch______New South Wales Dr G. Mason______Victoria Dr A. Darling______Victoria Miss R. McAleer, AM____ Western Australia Dr A.P. Dorevitch______Victoria Prof. S. Menziesv______New South Wales Dr J.P. Dowling______Victoria Dr D. Muir______New South Wales Dr R.E.T. Duhig______Queensland Prof. H.K. Muller______Tasmania Dr B. Dutta______New South Wales Prof. R. Penny, AO_____ New South Wales Dr R.B. Dymock______South Australia Prof. H.M. Prince______Victoria A/Prof. D. Ellis______South Australia Dr A. Ryan______Victoria Dr J. Farnsworth______Queensland Dr G. Strutton______Queensland Dr A. Fischer______New South Wales Dr J. Sullivan______Queensland Dr D.S. Forbes______New South Wales Dr S. Swain______Victoria Dr J. Fryer______New South Wales Dr J. Tversky______Victoria Dr A. Gramp______South Australia Prof. D. Weedon, AO____ Queensland Dr W.A.D. Griffiths______United Kingdom Dr R.A. Williams______Victoria Prof. G. Halliday______New South Wales Prof. K. Wolff______Austria Dr P.J. Heenan______Western Australia Cl. A/Prof. L. Yu______Western Australia Dr V.C. Howard______New South Wales

PBS Information: Authority Required. * Refer to the PBS Schedule for full details. stay confident. Please refer to the Product Information before prescribing *Estimated 777,000+ patient-years of cumulative (available from http://www.janssen.com.au/Stelara_PI) 1,2 PASI: Psoriasis Area and Severity Index. STELARA® ustekinumab (rmc) vials MINIMUM PRODUCT INFORMATION (Plaque psoriasis, psoriatic exposure from 7+ years’ clinical use. In psoriasis: 5 years arthritis, *Crohn’s disease) INDICATIONS: Moderate to severe plaque psoriasis in adults who are candidates for photo- or systemic therapy; signs 1,3 and symptoms of active psoriatic arthritis in adults where response to previous non-biological DMARD therapy has been inadequate; *moderately to PASI 75/90 response data, 5+ years safety severely active Crohn’s disease in adults who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a 1,3–5 1 TNFα antagonist or have medical contraindications to such therapies. DOSE: Psoriasis: Subcutaneous injection. 45 mg at Weeks 0 and 4, then every observations, 4 times a year dosing (after 2 initial doses). 12 weeks. Alternatively, in patients weighing >100 kg, 90 mg at Weeks 0 and 4, then every 12 weeks. If inadequate response, consider treatment every 8 weeks. Discontinue if no response after 28 weeks. Psoriatic Arthritis: Subcutaneous injection. 45mg at Weeks 0 and 4, then every 12 weeks. Some patients weighing >100kg received a 90mg dose in clinical trials and observed a clinical benefit. Discontinue if no response after 28 weeks. *Crohn’s Disease: Single initial intravenous tiered dose based on body weight using STELARA 130 mg vial (weight ≤ 55kg = 260 mg [2 vials]; weight > 55kg to ≤ 85 kg = 390 mg [3 vials]; weight > 85 kg = 520 mg [4 vials]). Then subcutaneous injection. 90 mg 8 weeks after the intravenous dose, then every 8 weeks. In some patients a subcutaneous dose of 90 mg 8 weeks after the intravenous dose, then every 12 weeks may be acceptable according to clinical judgment. Consider discontinuing if no evidence of benefit by Week 16. CONTRAINDICATIONS: Severe hypersensitivity to ustekinumab or to any of the excipients. Do not administer to patients with a clinically important active infection. PRECAUTIONS: Serious infections: STELARA may increase risk of infections and reactivate latent infections. Serious bacterial, fungal and viral infections have been observed. Use with caution in patients with chronic or recurrent infections. Tuberculosis (TB): Evaluate for TB prior to initiating treatment. Do not administer to patients with active TB. Treat latent TB before administration. Consider anti-TB therapy in patients with suspected TB. Monitor patients for TB. Malignancies: STELARA may increase risk of malignancies. Malignancies have been observed. Use with caution in patients with known malignancy or history of malignancies. Patients should be monitored for the appearance of non-melanoma skin cancer. Hypersensitivity reactions: Discontinue immediately if serious hypersensitivity reactions including anaphylaxis and angioedema occurs. Immunisations: Do not give live bacterial or viral vaccines. Consider secondary transmission of live vaccines from contacts. Immunosuppression: STELARA should not be used in combination with photo- or systemic therapy. Immunotherapy: Use with caution in patients receiving allergy immunotherapy. Reversible Posterior Leukoencephalopathy Syndrome (RPLS): If RPLS is suspected, STELARA should be discontinued and appropriate therapy instituted. Serious Skin Conditions: Physicians should be alert for symptoms of erythrodermic psoriasis or exfoliative dermatitis. STELARA should be discontinued if a drug reaction is suspected. Use in Pregnancy: Category B1. ADVERSE EFFECTS: Serious: serious infections and malignancies. Common: URTIs, nasopharyngitis, dizziness, headache, *oropharyngeal pain, diarrhoea, nausea, *vomiting, pruritus, back pain, myalgia, arthralgia, fatigue, injection site erythema, injection site pain. See full PI for other adverse effects. Adverse events: serious 1 P IS A S cardiovascular events, suicidality, hypersensitivity (including rash, urticaria), serious hypersensitivity reactions including anaphylaxis and angioedema. S R O A T R I H PRESENTATION: Pack of 1 single use 45 mg vial for subcutaneous use, and Store I *pack of 1 single use vial for intravenous use (Crohn’s disease only). R R A at 2°C – 8°C. Refrigerate. Do not freeze or shake. Protect from light by storing in original carton. Date of preparation: 8 March 2017 O I T T S I

C I

P S

*Please note changes to Product Information as *italicised text 1 REFERENCES: 1. STELARA (ustekinumab) Approved Product Information 28 February 2017. 2. Janssen data on file. 3. Kimball AB et al. J Eur Acad Dermatol Venereol 2013;27:1535-1545. 4. Langley RG et al. Br J Dermatol 2015;172:1371-1383. 5. Papp KA et al. Br J Dermatol © C 2013;168:844-854. Janssen-Cilag Pty Ltd 2017. Trademarks and brand names are the R 1 OH E property of Johnson & Johnson, its affiliates or third party owners. Janssen Cilag Pty Ltd, ABN N’ AS 47 000 129 975. 1-5 Khartoum Road, Macquarie Park NSW 2113. Phone: 1800 226 334. S DISE Date of preparation: April 2017. MKT-STE-AU-0141 JANS1898/EMBC

6 HONORARY MEMBERS PROGRAM The plenary sessions will be held in the Pyrmont Theatre. Concurrent sessions will be held on level 2 across the Meeting and Parkside rooms.

SPECIAL EVENT

The following satellite meeting is being held in association with the College ASM:

AUSTRALIAN DERMATOLOGY NURSES’ ASSOCIATION 16TH ANNUAL NATIONAL CONFERENCE International Convention Centre Sydney Saturday 6 May and Sunday 7 May 2017

ADNA Sponsor:

REGISTRATION

The registration desk will be located in the Pyrmont Theatre Foyer. The registration desk will open on Saturday 6 May from 0700 and throughout the meeting. The College secretariat office located in Meeting Room C2.4 will be open from 1000 to 1600 daily.

MEET THE ACD STAFF!

The College will have its own stand at booth 111-114 in the trade exhibition, manned by members of the College staff. Come meet us and find out what we can do for you. Pick up some leaflets, find out about the website and check up on your Continuing Professional Development (CPD) points.

NAME BADGES

Name tags must be worn at all times. Delegates without a name badge may be refused entry to sessions and to the trade exhibition.

CONFERENCE APP

The College is offering a free downloadable app for the Annual Scientific Meeting. To download the app please search for ACD2017ASM in your app store. The app can also be viewed in a web browser at acd2017asm.mobi Features of the app include: Building your own personal program of sessions. Note that recording your session selections on the app does not confirm your attendance at any of the social functions or sponsored symposia sessions. Please see staff at the ASM registration desk if you have not pre-registered for these sessions and wish to attend. Participating in the exhibition passport competition View all trade details and easily be able to contact them after the ASM All delegates will have a QR code on their name badge which can then be used by trade to collect your details to be able to send you further information. Please see the staff at the registration desk if you are having any issues with using the app.

7 EXHIBITOR PASSPORT COMPETITION

This year the exhibitor passport competition will be run through the conference app. Each trade exhibitor will have a sign at their booth with a QR code. To enter the competition for each booth:

1 Scan the barcode at the exhibition booth using the scan function in the menu of the app. Note that you must allow the app to access your phone’s camera.

2 A question about the exhibitor will pop up, please answer this question to submit for entry for this booth.

3 You can view all of the exhibitors you have answered questions for in the Exhibitor Passport Entries. Note that once an answer is submitted you cannot go back to view or change this. Delegates are required to answer 20 exhibitor questions to qualify for a complete entry. Prizes will be awarded during the lunch break on Tuesday 9 May in the Exhibition Hall. Open only to dermatologists and vocational trainees in dermatology.

TRADE EXHIBITION SPEAKERS’ PREPARATION The trade exhibition will be in Hall 1. It will be open on the following days: ROOM Saturday 6 May from 1000 to 1600 (1245 official opening) The speakers’ preparation room is located in Meeting Room C2.1 of Sunday 7 May from 1000 to 1600 the International Convention Centre Monday 8 May from 1000 to 1600 Sydney. The room is staffed daily. The technician will be on hand one hour Tuesday 9 May from 1000 to 1345 before the start of each session, then The morning tea, lunch and afternoon tea breaks will be held in the trade 30 minutes after the close of the final exhibition. Please note that separate dietary catering tables will be set up in session. Presenters are encouraged to hand their presentations in at least two the exhibition area for those who have submitted dietary requests. hours before required onstage, or the day before if presenting in the morning. Awards for outstanding exhibitors AWARDS Awards for the outstanding exhibits will be announced on Tuesday 9 May 2017. The categories of award are: If there are papers of sufficient merit, Most outstanding display of 9 sqm or less in size the following awards/prizes will be awarded: Most outstanding display of 18 sqm to 27 sqm in size Best research paper read at the Most outstanding display of 36 sqm in size, or larger Annual Scientific Meeting – F. & E. Bauer Foundation Prize The award will be decided by a panel of judges. Best paper in the Registrars’ Forum Kindly sponsored by

Best poster presentations (two prizes) Kindly sponsored by

Best paper or poster presentation by a New South Wales Registrar, the Eileen Collins Memorial Prize – funded by the New South Wales Faculty

Best paper in Contact Dermatitis, the John Fewings Memorial Prize – funded by the Skin & Cancer Foundation Victoria

8 Cosentyx Efficacy

He was so excited to have been given a greater opportunity to achieve clear skin*1

*At week 52, PASI 100 responses to secukinumab and ustekinumab were 45.9% and 35.8% respectively (p=.0103). Primary study endpoint was achieved with secukinumab demonstrating superiority in PASI 90 response (79%) to ustekinumab ( 57.6 % ; p<.0001) at Week 16.

PBS Information: Section 85 Authority Required for the treatment of severe chronic plaque psoriasis, active ankylosing spondylitis and severe psoriatic arthritis. Refer to PBS Schedule for full Authority information. See approved Product Information before prescribing. Approved Product Information available on request. For the most up-to-date Product Information, go to: https://www.novartis.com.au/products/healthcare-professionals COSENTYX® (secukinumab) Indication: Treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. Treatment of adult patients with active psoriatic arthritis when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate. Treatment of adult patients with active ankylosing spondylitis. Dosage and administration: Plaque psoriasis: The recommended dose is 300 mg by subcutaneous injection with initial dosing at weeks 0, 1, 2 and 3, followed by monthly maintenance dosing starting at week 4. Each 300 mg dose is given as two subcutaneous injections of 150 mg. Psoriatic arthritis: The recommended dose is 150 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2 and 3, followed by monthly maintenance dosing starting at Week 4. For patients who are anti-TNFα inadequate responders or patients with concomitant moderate to severe plaque psoriasis, the recommended dose is 300 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2 and 3, followed by monthly maintenance dosing starting at Week 4. Each 300 mg dose is given as two subcutaneous injections of 150 mg. Ankylosing spondylitis: The recommended dose is 150 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2 and 3, followed by monthly maintenance dosing starting at Week 4. Contraindications: Severe hypersensitivity reactions to the active substance or to any of the excipients. Clinically important, active infections. Precautions: Infections: Caution in patients with chronic or history of recurrent infection. If a patient develops a serious infection, the patient should be closely monitored and Cosentyx should not be administered until the infection resolves. Anti-tuberculosis therapy should be considered prior to initiation in patients with latent tuberculosis. Cosentyx should not be given to patients with active tuberculosis. Crohn’s disease: Caution should be exercised, when prescribing to patients with inflammatory bowel disease. Exacerbations, in some cases serious, occurred during clinical trials in plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. In addition, new onset inflammatory bowel disease cases occurred in clinical trials. Patients should be monitored for signs and symptoms of inflammatory bowel disease. Hypersensitivity reactions: Rare cases of anaphylactic reactions have been observed during clinical trials. Administration should be discontinued immediately and appropriate therapy initiated if an anaphylactic or other serious allergic reaction occurs. Latex-sensitive individuals: The removable cap of the Cosentyx pre-filled syringes/pen contains a derivative of natural rubber latex. Vaccinations: Cosentyx should not be given concurrently with live vaccines. Pregnancy: Cosentyx should be used during pregnancy only if the benefits clearly outweigh the potential risks. Breast-feeding: Caution should be exercised when Cosentyx is administered to a woman who is breast-feeding. Interactions: Live vaccines should not be given concurrently with Cosentyx. Side effects: Very common (≥10%): nasopharyngitis. Common (1 to 10%): upper respiratory tract infection, rhinitis, pharyngitis, oral herpes, diarrhoea, urticaria, rhinorrhoea, headache, nausea, hypercholesterolemia. Uncommon (0.1 to 1%): sinusitis, tonsillitis, oral candidiasis, neutropenia, tinea pedis, otitis externa, conjunctivitis. In clinical trials, major adverse cardiovascular events were rarely observed in patients receiving secukinumab. In the overall secukinumab program, the exposure adjusted incidence rates of adjudication-confirmed cases per 100 patient-years for secukinumab was 0.40 versus 0.39 for placebo. Elevations (mainly CTCAE Grade 1 and Grade 2) in cholesterol, triglycerides and hepatic transaminases were also observed during clinical trials in patients with psoriatic arthritis and ankylosing spondylitis. ( cos171016m ). Reference: 1. Blauvelt A, et al. JAAD 2016. http://dx.doi.org/10.1016/j.jaad.2016.08.008. ® Registered trademark of Novartis. Novartis Pharmaceuticals Australia Pty Limited ABN 18 004 244 160. 54 Waterloo Road, Macquarie Park NSW 2113. Ph (02) 9805 3555. Date of preparation: March 2017. AU-1489. CRD2756. 9

NOV2756 Cosentyx Journal Ad-Efficacy-ACD_AU-1489_v1.1.indd 1 10/04/2017 11:39 am INTERNATIONAL CONVENTION CENTRE SYDNEY

The ASM sessions will be held on Level 2 of the Convention Centre and the trade exhibition in Hall 1 of the Exhibition Centre of the ICC Sydney.

LEVEL 2 FLOOR PLAN

ASM REGISTRATION DESK

TO TRADE EXHIBITION IN HALL 1

10 ROOM ALLOCATIONS

Pyrmont Theatre______ASM Plenary and Concurrent Sessions

Pyrmont Theatre Foyer______ASM Registration Desk and College History Display

Meeting Room C2.1______Speaker Preparation Room

Meeting Room C2.2 and C2.3______ADNA 16th National Conference Sessions and Moh’s Surgery Session

Meeting Room C2.4______College Secretariat

Meeting Room C2.5______Meeting Room

Meeting Room C2.6______Meeting Room

Parkside 1______Conference Dinner

Parkside 2______ASM Concurrent Sessions

Hall 1______Trade Exhibition

ACCESS TO THE ICC SYDNEY

PUBLIC TRANSPORT AND TAXIS The ICC Sydney is located in the heart of Sydney’s Darling Harbour. ICC Sydney is easily accessible by public transport, including light rail, ferry and train and is only a 10 minute walk from Central and Town Hall train stations. Taxis are available at all times throughout the inner city.

PARKING Address: 14 Darling Drive, Sydney, NSW 2000 ICC Sydney Exhibition Centre Car Park (Car Park 1) Proceed to Level 2 in the lift. Operating hours: Monday to Sunday - 24 hours Parking rates: 0 - 1 hour $18.00 1 - 2 hours $30.00 2 - 3 hours $38.00 3 - 4 hours $44.00 4+ hours $49.00 Lost ticket $49.00 Per entry per day Night rate $28.00 Entry after 6pm and exit before 4.00am

11 CONFERRING CEREMONY TRANSPORT

Return buses have been organised to transport delegates to/from The University of Sydney for the Conferring Ceremony. Please proceed to Iron Wharf Place outside the Convention Centre of the ICC Sydney with buses departing regularly from 1545-1645.

GROUND LEVEL FLOOR PLAN

Buses will depart regularly from the University starting at 1900 (returning to the ICC Sydney). Last bus departs at 2015.

12 PROGRAM AT A GLANCE

The Convenor of the scientific program is Associate Professor Samuel Zagarella, supported by Dr Ian Hamann and Dr Monisha Gupta as Co-Convenors and the Scientific Meetings Steering Committee of the College.

SATURDAY 6 MAY 2017 SUNDAY 7 MAY 2017 CONTACT ACNE SESSION DERMATITIS 0730-0830 SESSION Pyrmont Theatre 0730-0830 Parkside 2 OPENING BY PRESIDENT AND WELCOME TO COUNTRY 0830-0845 GLOBAL Pyrmont Theatre PSORIASIS DERMATOLOGY SYMPOSIUM SYMPOSIUM ADNA MEETING PLENARY SESSION 1 ADNA MEETING 0845-1015 0845-1015 0900-1030 0845-1015 0845-1030 Pyrmont Theatre Pyrmont Theatre Meeting Rooms C2.2 and Parkside 2 Meeting Rooms C2.2 C2.3 and C2.3 MORNING TEA ADNA MORNING TEA MORNING TEA 1015-1100 ADNA MORNING TEA 1030-1100 1015-1100 Trade Exhibition - Hall 1 Trade Exhibition - Hall 1 1030-1100 Trade Exhibition - Hall 1 Trade Exhibition - Hall 1 REGISTRARS’ AND ADNA MEETING ADNA MEETING FELLOWS UPDATE 1100-1230 PLENARY SESSION 2 1100-1200 1100-1230 Meeting Rooms C2.2 and 1100-1230 Meeting Rooms C2.2 Pyrmont Theatre C2.3 Pyrmont Theatre and C2.3 ADNA LUNCH LUNCH ADNA LUNCH 1230-1330 LUNCH 1200-1300 1230-1345 Trade Exhibition - Hall 1 1230-1345 Trade Exhibition - Hall 1 Trade Exhibition - Hall 1 Trade Exhibition - Hall 1 ADNA MEETING ADNA MEETING 1330-1430 1300-1515 SURGERY UPDATE Meeting Rooms C2.2 and REGISTRARS’ AND Meeting Rooms C2.2 FOR GENERAL C2.3 CLINICOPATHOLOGICAL PATHOLOGICAL FELLOWS UPDATE and C2.3 DERMATOLOGISTS CORRELATION 1345-1515 ADNA AFTERNOON TEA 1345-1515 1345-1515 Pyrmont Theatre 1430-1500 Pyrmont Theatre Parkside 2 Trade Exhibition - Hall 1

AFTERNOON TEA AFTERNOON TEA 1515-1600 ADNA MEETING 1515-1600 Trade Exhibition - Hall 1 1500-1630 Trade Exhibition - Hall 1 Meeting Rooms C2.2 SURGERY UPDATE and C2.3 REGISTRARS’ AND FOR GENERAL FELLOWS UPDATE DERMATOLOGISTS 1600-1730 1600-1730 Pyrmont Theatre Parkside 2

SPONSORED SPONSORED SYMPOSIUM SYMPOSIUM

MOHS SURGERY SESSION CONFERRING CEREMONY 1730-1930 1700-1900 1730-1830 1730-1830 Rooms C2.2 and C2.3 Great Hall, University of Sydney Pyrmont Theatre Parkside 2 Buses depart the ICC Sydney from 1545. FOUNDERS’ COCKTAIL PARTY 1900-2000 MacLaurin Hall, University of Sydney Buses will depart regularly from the University starting at 1900 (returning to the ICC Sydney). Last bus departs at 2015.

CONFERENCE DINNER 1930-2330 Parkside Ballroom

*Program subject to change

13 MONDAY 8 MAY 2017 TUESDAY 9 MAY 2017 DERMATOLOGY HOSPITATLISTS GENITAL DERMATOLOGY PAEDIATRIC DERMATOLOGY REGISTRARS’ FORUM SESSION 0730-0830 0730-0830 0730-0830 0730-0830 Pyrmont Theatre Parkside 2 Pyrmont Theatre Parkside 2

MEDICAL DERMATOLOGY ART OF DERMATOLOGY AND NON-MELANOMA SKIN CANCER COSMETIC DERMATOLOGY FOR UPDATE OTHER SURPRISES SYMPOSIUM GENERAL DERMATOLOGISTS 0845-1015 0845-1015 0845-1015 0845-1015 Pyrmont Theatre Parkside 2 Pyrmont Theatre Parkside 2

MORNING TEA MORNING TEA 1015-1100 1015-1100 Trade Exhibition - Hall 1 Trade Exhibition - Hall 1

PLENARY SESSION 3 PLENARY SESSION 4 AND AWARDING OF PRIZES 1100-1230 1100-1230 Pyrmont Theatre Pyrmont Theatre

LUNCH LUNCH 1230-1345 1230-1345 Trade Exhibition - Hall 1 Trade Exhibition - Hall 1

ETHICS AND PROFESSIONALISM CONGRESS WHAT’S NEW IN JOURNALS FREE PAPERS 1345-1515 1345-1515 1345-1515 Pyrmont Theatre Pyrmont Theatre Parkside 2

AFTERNOON TEA 1515-1600 Trade Exhibition - Hall 1

ETHICS AND PROFESSIONALISM CONGRESS 1600-1645 REGISTRARS’ TEACHING SESSION Pyrmont Theatre 1600-1730 Parkside 2 ACD ANNUAL GENERAL MEETING 1645-1730 Pyrmont Theatre SPONSORED SYMPOSIUM SPONSORED SYMPOSIUM

1730-1830 1730-1830 Pyrmont Theatre Parkside 2

*Program subject to change

14 SCIENTIFIC MEETING THE AUSTRALASIAN COLLEGE OF DERMATOLOGISTS 2017 ASM SATURDAY 6 MAY 2017

0700-1700 REGISTRATION DESK OPEN

0830-0845 WELCOME TO COUNTRY Ms Y. Weldon OPENING BY PRESIDENT A/Prof. C. Baker Room: Pyrmont Theatre

0845-1015 PLENARY SESSION 1 Room: Pyrmont Theatre Chair: A/Prof. C. Baker

0845 Dr A. Marghoob Nevogenesis: Insights gained from dermoscopy 0905 Dr S. Fosko Targeted therapy comes to basal cell carcinoma: Hedgehog inhibitors 0925 Prof. R. Rapini Diagnostic criteria in dermatology 0945 Prof. A. Anstey Transformative case reports in dermatology: Hunting for the needle in the haystack 1005 Questions 1015 END OF SESSION

1015-1100 MORNING TEA IN THE TRADE EXHIBITION, HALL 1

1100-1230 REGISTRARS’ AND FELLOW UPDATE SESSION 1 Room: Pyrmont Theatre Chair: Dr I. Hamann

1100 Dr A. Marghoob Benefits of leveraging technology towards melanoma detection 1120 A/Prof. P. Guitera ANZMTG 02.12 the RADICAL trial – RADiotherapy or imiquimod in complex lentigo mALigna 1132 Dr D. Kennedy Dermatology and medications in women of childbearing age 1144 Dr E. McMeniman Update on hidradenitis suppuritiva 1156 Dr A. Saracino Update on cutaneous lupus erythematosus 1208 Dr N. Wines Advances in obstetric dermatology 1220 Questions 1230 END OF SESSION

1230-1345 LUNCH IN THE TRADE EXHIBITION, HALL 1

15 THE AUSTRALASIAN COLLEGE OF DERMATOLOGISTS 2017 ASM SATURDAY 6 MAY 2017

1345-1515 REGISTRARS’ AND FELLOW UPDATE 1345-1515 SURGERY UPDATE FOR GENERAL SESSION 2 DERMATOLOGISTS 1 Room: Pyrmont Theatre Room: Parkside 2 Chair: Dr M. Gupta Chair: Dr M. Lee 1345 A/Prof. M. Schifter 1345 Dr H. Smith Oral medicine for dermatologists: Oral Strategies for preventing surgical site manifestations and complications of infection in dermatologic surgery: The latest dermatological diseases evidence 1357 Dr K. Kerkemeyer 1355 Dr L. Young Lichen planopilaris: A retrospective study Perineural invasion present exclusively of 32 cases in an Australian tertiary referral in central tissue blocks of Mohs surgical hair clinic excisions of basal cell carcinoma 1409 Dr L. Yip 1405 Dr S. Fosko Alopecia update Cartilage grafts for nasal defects: When less 1421 Dr M. Rodrigues and Dr M. Gupta is best Update vitiligo and other pigmentary 1425 Dr K. Lun disorders Stretch, an inconspicuous BFF 1433 Dr E. Forward 1435 Dr. P Chen Treatment of rosacea: Update on general Is bupivacaine a useful adjunct to management approach and topical lignocaine in dermatologic surgery? treatment options 1445 Dr K. Tumuluri 1445 Dr A. Howard Periocular surgical procedures Management tips from a nail clinic 1505 Questions 1457 Questions 1515 END OF SESSION 1515 END OF SESSION

1515-1600 AFTERNOON TEA IN THE TRADE EXHIBITION, HALL 1

1600-1730 REGISTRARS’ AND FELLOW UPDATE 1600-1730 SURGERY UPDATE FOR GENERAL SESSION 3 DERMATOLOGISTS 2 Room: Pyrmont Theatre Room: Parkside 2 Chairs: A/Prof. S. Zagarella Chair: Dr S. Lee 1600 A/Prof. S. Zagarella and Dr K. Chen 1600 Dr S. Fosko, Dr I. Hamann, Dr D. Lim Evidenced based medicine lecture series and Dr E. Upjohn 1610 Mr M. Barbic Ask the experts’. Defects presented with Safety of medical records and medical panel discussing repair options communication 1632 Dr R. Rosen and Dr T. Stewart 1620 A/Prof. A. Oakley Surgical practices of Australian Clinical photography in your dermatology dermatologists practice 1640 Dr C. Reddy 1630 Dr T. Blake Nasal repairs, a plastic surgical perspective Desmoplastic trichoepithelioma - a case 1700 Dr R. Cocciolone series and review of management Surgical pearls: Facilitating wound closure 1640 Dr P. Lowe in fragile skin and a burrow’s free A to T The lost art of compounding advancement flap 1650 Dr V. Tng 1710 Dr L.J. Leow Dermatological manifestations of Diagrammatically simple but technically inflammatory bowel disease complex: Z-plasty, the nasolabial flap and the keystone flap 1700 Questions 1720 Questions 1730 END OF SESSION 1730 END OF SESSION

16 THE AUSTRALASIAN COLLEGE OF DERMATOLOGISTS 2017 ASM SATURDAY 6 MAY 2017

1730-1830 SPONSORED SYMPOSIUM 1730-1830 SPONSORED SYMPOSIUM Room: Pyrmont Theatre Room: Parkside 2 Chair: Prof. G. Varigos

A/Prof P. Fernandez-Peñas and Dr J. A/Prof. P. Foley, Mr G. Varkanis and Ms Sullivan P. Shakespeare IL-17 inhibition in psoriasis: Hard to From drug discovery to reimbursement: treat psoriasis, quality of life aspects How clinicians, industry and This symposium will touch on two key government work together to deliver topics with IL-17 inhibition in psoriasis. better outcomes for your patients It reviews role of IL-17 inhibition in Regulatory and reimbursement authority management of hard to treat psoriasis expectations of clinical data are higher phenotypes. It also discusses the impact than they have ever been, and industry of severe psoriasis on QoL, touching on is doing all it can to address these the relationship between PASI and QoL. needs through both conventional and 1730 END OF SESSION novel approaches. Join us for an open discussion amongst our panel of clinical, industry and health economic experts, focusing on key milestones along the drug development pathway and what this means for you and your clinical practice. A/Prof. Peter Foley (Clinical Dermatologist, Director of Research at the Skin & Cancer Foundation Inc., and Head of Dermatology Research at St Vincent’s Hospital Melbourne), Mr George Varkanis (Celgene Vice President & Managing Director, Australia & New Zealand), and Ms Penny Shakespeare (First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health), will offer representative perspectives from the clinician, industry and government respectively, on drug discovery through clinical trial development to medicines access for the Australian patient. 1730 END OF SESSION

1730-1930 MOHS SURGERY SESSION Room: Meeting Rooms C2.2 and C2.3

social program 1930-2330 CONFERENCE DINNER, PARKSIDE BALLROOM International Convention Centre Sydney

17 AUSTRALIAN DERMATOLOGY NURSES’ ASSOCIATION 16TH NC SATURDAY 6 MAY 2017

0800-1700 REGISTRATION DESK OPEN

0830-0845 WELCOME TO COUNTRY Ms Y. Weldon OPENING BY PRESIDENT A/Prof. C. Baker Room: Pyrmont Theatre

0845-1030 SESSION 1 1330-1430 SESSION 3 Rooms: Meeting Rooms C2.2 and C2.3 Rooms: Meeting Rooms C2.2 and C2.3

0845 Ms S. Temby 1330 Dr M. Hunt Welcome and housekeeping 1400 Mr P. Faga, RN 0900 Dr S. Smithson Surgical treatment of vitiligo. A new Drug rashes standard of care? 0930 Dr P. Artemi 1430 END OF SESSION What’s new in adult acne? 1000 Dr S. Smith 1430-1500 AFTERNOON TEA IN THE TRADE Hidradentis suppuravitas EXHIBITION, HALL 1 1030 END OF SESSION 1500-1630 SESSION 4 1030-1100 MORNING TEA IN THE TRADE Rooms: Meeting Rooms C2.2 and C2.3 EXHIBITION, HALL 1 1500 Dr M. Whitfeld 1100-1230 SESSION 2 Scabies research in Fiji Rooms: Meeting Rooms C2.2 and C2.3 1530 Cl. A/Prof. S. van Nunen Ticks and bites 1100 Keynote Speaker - Ms L. Aldredge, RN State of dermatology 1600 Ms M. Weaich, RN Excimer UV light treatment 1200 C. Smith, RN ADNA constitution and committee 1630 END OF SESSION 1230 END OF SESSION 1900 EGO DINNER 1230-1330 LUNCH IN THE TRADE EXHIBITION, Kazbah Darling Harbour, Harbourside HALL 1 Shopping Centre, Darling Harbour

Demonstrated relief for your eczema patients

FILAGGRIN CERAMIDE MIRACARE TECHNOLOGY TECHNOLOGY TECHNOLOGY

cetaphil.com.au

18 THE AUSTRALASIAN COLLEGE OF DERMATOLOGISTS 2017 ASM SUNDAY 7 MAY 2017

0700-1700 REGISTRATION DESK OPEN

0730-0830 ACNE 0730-0830 CONTACT DERMATITIS Room: Pyrmont Theatre Room: Parkside 2 Chair: Dr J-A. See Chair: A/Prof. R. Nixon

0730 Dr J-A. See 0730 Dr D. Maor Introduction Intradermal testing for autoimmune progesterone dermatitis – should we be 0731 Dr J. Cargnello basing our diagnosis on it? Hormonal acne update 0740 Dr P. Dickison Hand dermatitis and chronic urticaria 0738 Dr J-A. See and A/Prof. M. Rademaker secondary to gel nail varnish Panel - question and answer 0747 Dr L. Ly 0751 Dr J-A. See PatchCAMS (Contact Allergy Management System) database review of patients What’s new for 2017 referred for implant hypersensitivity 0755 Prof. M. Nielsen 0759 Dr V. Harris A new biophotonic treatment – explained! Nickel allergy: A bigger headache for patients with chest pain 0800 Prof. R. Paus 0806 Dr D. Maor Translational biology of the pilosebaceous Interesting clinical cases of contact dermatitis unit re-visited: Relevance to acne and 0816 Dr D. Slape hidradenitis Liverpool Hospital and the ring of fire: Anogenital contact dermatitis 0830 END OF SESSION 0823 Questions 0830 END OF SESSION

0845-1015 PSORIASIS SYMPOSIUM 0845-1015 GLOBAL DERMATOLOGY SYMPOSIUM Room: Pyrmont Theatre Room: Parkside 2 Chair: Dr J. Sullivan Chair: Dr M. Whitfeld

0845 Dr J. Sullivan, A/Prof. M. Rademaker 0845 Dr M. Whitfeld and Dr M. Gupta Introduction: Global dermatology for the Introduction Australian dermatologist 0850 Dr P. Dickison 0855 Dr J. Rhodes and Dr R. Saunderson Characteristics of itch in psoriasis: The results from a dermatology clinic Dermatology in East Timor 0900 Prof. R. Sinclair 0905 Dr M. Rodrigues Tildrakizumab, a selective IL-23p19 Pigment disorders in rural north India antibody, in the treatment of chronic plaque 0915 Dr L. Romani psoriasis: Results from two randomised, controlled, phase 3 trials New control initiatives for scabies in highly 0910 Dr A. Bhullar endemic populations The prevalence of synovitis and 0925 Dr T. O’Brien tenosynovitis in the small joints of the Aspects of leishmaniasis hands using ultrasonography in patients 0935 Dr N. Sharma with chronic plaque psoriasis but undiagnosed psoriatic arthritis Dermatology in Papua New Guinea: 0920 A/Prof. M. Rademaker Leprosy, examinations and more Australasian psoriasis collaborative 0945 Dr M. Tuicakau recommendations for methotrexate Improving skin health in the South Pacific - 0933 Dr D. Rubel meeting the need Australasian psoriasis collaborative (APC) recommendations for managing 0955 Panel discussion malignancy in the psoriatic patient 1015 END OF SESSION 0946 Dr M. Andrews Psoriasis in those planning a family, pregnant or breastfeeding. The Australasian psoriasis collaboration 1000 Panel discussion 1015 END OF SESSION

19 THE AUSTRALASIAN COLLEGE AUSTRALIAN DERMATOLOGY NURSES’ OF DERMATOLOGISTS 2017 ASM ASSOCIATION 16TH NC SUNDAY 7 MAy 2017 SUNDAY 7 MAY 2017

1015-1100 MORNING TEA IN THE TRADE 0800-1500 REGISTRATION DESK OPEN EXHIBITION, HALL 1 0900-1030 SESSION 5 1100-1230 PLENARY SESSION 2 Rooms: Meeting Rooms C2.2 and C2.3 Room: Pyrmont Theatre Chair: Dr M. Gupta 0900 Dr E. Dawes-Higgs Female genital dermatology: A brief 1100 Prof. A. Anstey introduction Phototherapy in eczema 0930 Annual General Meeting 1120 Dr P. Dickison 1000 Dr L. Sagi Serious games and innovative technology Interesting psoriasis case studies for dermatology education 1030 END OF SESSION 1130 Dr C. Scarff Why is it so hard to give negative 1030-1100 MORNING TEA IN THE TRADE feedback to underperforming specialist EXHIBITION, HALL 1 trainees? 1140 Prof. R. Rapini 1100-1200 SESSION 6 Mucinoses Rooms: Meeting Rooms C2.2 and C2.3 1155 Dr J. Frew 1100 Ms L. Aldredge, RN Drug induced hidradenitis suppurativa / Psoriasis acne inversa: A systematic review of case reports with insights into pathogenesis of 1130 A/Prof. G. Fischer disease Paediatric conditions that mimic abuse 1205 Dr L. Ge 1200 END OF SESSION A prospective 5-year Australian renal and 1200-1300 LUNCH IN THE TRADE EXHIBITION, liver organ transplant dermatology study HALL 1 1215 Dr R. Kelly Livedo racemosa: The relationship 1300-1515 SESSION 7 between lymphocytic and neutrophilic Rooms: Meeting Rooms C2.2 and C2.3 vasculitis 1225 Questions 1300 A/Prof. M. Schifter Oral dermatology 1230 END OF SESSION 1400 BDNG Representative 1230-1345 LUNCH IN THE TRADE EXHIBITION, Updates in British dermatology nursing HALL 1 1430 Dr S. Donoghue Weird and wonderful 1345-1515 CLINICOPATHOLOGICAL PATHOLOGICAL 1500 Ms S. Temby CORRELATION Award presentations and member’s draw Room: Parkside 2 1515 END OF SESSION Chairs: Dr K. Crotty and Dr G. Gottschalk

11 interesting cases to be presented and discussed with lots of audience participation! 1515 END OF SESSION

1515-1600 AFTERNOON TEA IN THE TRADE EXHIBITION, HALL 1

20 THE AUSTRALASIAN COLLEGE OF DERMATOLOGISTS 2017 ASM SUNDAY 7 MAY 2017

Sunday 7 May 2017, 5.00pm Honorary Fellow Founders’ Medal for Procedural The Great Hall, Professor Jean Bolognia Dermatology for 2016 The University of Sydney, Professor John Hawk Dr Rebecca Nguyen Professor John McGrath Science Road, President’s Medal for Pharmacology Camperdown NSW 2050 International Outreach Award for 2016 Dr Timothy O’Brien Dr Sarah Smithson

PROGRAM Mervyn Gold, OAM, Award Adrian Johnson Memorial Prize for Dr Neville Collins 2016 Processional Music Dr Casey Rowe Trumpet Voluntary Dr Ian McCrossin Eileen Collins Memorial Prize for Certificate of Service Academic Procession 2016 Dr Bob Corderoy The audience is requested to stand Dr Andrew Lee when the academic procession enters Mr Tony Moore Oath of Ethics the hall; and to remain standing for the The new Fellows will affirm the Oath Graduate from the ACD Mohs singing of the National Anthems of of Ethics. Australia and New Zealand. Micrographic Surgery Training Program Dr Peggy Chen The Oath will be recited by Dr Opening Proceedings Dr Dougal Coates Georgina Lyons. Associate Professor Chris Baker, President of the Australasian College Fellows elected under Clause 3.2 of Music Interlude of Dermatologists, will declare the the College Constitution Battle Suite Dr Mark Darling proceedings open and address the assembly Dr Lior Sagi John Reid Oration Belisario Award for Academic Professor Werner Sinclair To be given by The Honourable Dermatology Dr Ritva Vyas Michael Kirby AC CMG Professor Gary Halliday Dr Ebrahim A K Abdulla Conclusion Induction of New Fellows The assembly is requested to stand Silver Medal Dr James Butler AM Dr Austen Anderson as the academic procession leaves the Dr Friyana Bhabha auditorium. Associate Professor Rosemary Nixon Dr Melissa Carroll Associate Professor Stephen Shumack OAM Dr Mark Cicchiello Recessional Music Dr John Sippe Dr John Frew Trumpet Tune Dr Daniel Gaffney Certificate of Meritorious Service Music Dr Pamela Brown Dr Dallas Gramp Modest Brass Dr Amy Kline Dr Judith Cole Dr Lena Ly Dr David Cook Carillonist/Organist Dr Georgina Lyons Amy Johansen Dr Alan Donnelly Dr Emma Mooney Dr Timothy Elliott Dr Rebecca Nguyen Guests of Honour Associate Professor Gregory Goodman Dr Christopher Ross His Excellency General The Dr Jeremy Horton Dr Salvatore Scuderi Honourable David Hurley AC DSC Dr Gillian Marshman Dr Deshan Sebaratnam (Ret’d), Governor of New South Wales Dr Jennifer Menz Dr Devita Surjana and Mrs Linda Hurley Dr Catherine Reid Dr Bonnie Swan Dr Michael Rich Dr Matthew Warren Dr Ivan Robertson Dr Annaliesa Wright Guests of the conferring ceremony Clinical Associate Professor Duncan are invited to stay and enjoy light Australasian College of Dermatologists Stanford refreshments in the MacLaurin Hall. Dr Clare Tait Travelling Fellowship from 2016 Dr Lachlan Warren Examinations and Ken Paver Medal for Buses will depart regularly from the Medical Dermatology For 2016 University starting at 1900 (returning Dr Georgina Lyons to the ICC Sydney). Last bus departs at 2015.

21 THE AUSTRALASIAN COLLEGE OF DERMATOLOGISTS 2017 ASM MONDAY 8 MAY 2017

0700-1700 REGISTRATION DESK OPEN

0730-0830 GENITAL DERMATOLOGY 0730-0830 PAEDIATRIC DERMATOLOGY Room: Pyrmont Theatre Room: Parkside 2 Chairs: Dr C. Drummond and Dr I. McCrossin Chair: Dr L-C. Wong

0730 Dr K. Deen 0730 A/Prof. G. Fischer Imiquimod in the treatment of penile The management of paediatric vulval intraepithelial neoplasia: An update conditions 0739 Dr E. Dawes-Higgs 0740 Dr A. Halbert An update on the classification of vulval Update on the use of topical and oral squamous intraepithelial lesions sirolimus in paediatric dermatology 0746 Dr V. Harris 0750 Dr P. Hogan Development and validation of vulval What I have learned - paediatric disease quality of life index (VDQLI) dermatology pearls 0753 Dr Y. Nguyen 0800 Dr L. Warren The association between chronic Update - infestations and dermatophytes vulvovaginal candidiasis and use of the 0810 Dr D. Orchard levonorgestrel-releasing intrauterine Update in the topical management of system ichthyoses 0800 A/Prof. A. Hall and A/Prof. G. Fischer 0820 Dr O. Wargon Female and male genital dermatology - all Clinical spectrum of CM-AVM syndrome you need to know 0830 END OF SESSION 0830 END OF SESSION

0845-1015 MEDICAL DERMATOLOGY 0845-1015 ART OF DERMATOLOGY AND OTHER UPDATE SURPRISES Room: Pyrmont Theatre Room: Parkside 2 Chair: Dr H. Fallah Chair: Dr P. Brown

0845 Prof. A. Anstey 0845 Dr T. O’Brien Publication ethics Painting the skin 0900 Prof. R. Sinclair 0900 A/Prof. S. Kossard Treatment of chronic telogen effluvium with Dermatopathology and abstract art oral minoxidil photography 0910 Dr A. Saracino Systemic sclerosis and morphoea: Role of a 0915 Cl. A/Prof. C. Commens dermatologist Ethics and dermatology. Lessons learned 0920 Dr R. Rosen 0930 Dr M. Lane-Brown Review of 10 year data of axillary The art of dermatology hyperhidrosis therapy 0945 Dr C. Quirk 0930 Dr D. Rubel The art of dermatology: Satisfactory Biologics beyond psoriasis outcomes 0940 Dr A. Gin The classification and diagnostic algorithm 1000 Dr P. Brown for primary lymphatic dysplasia: An update Therapy is a partnership for 2017 1015 END OF SESSION 0950 Dr T. Papps Contribution to medical dermatology – the Australian cutaneous lymphoma multidisciplinary team 1000 Questions 1015 END OF SESSION

1015-1100 MORNING TEA IN THE TRADE EXHIBITION, HALL 1

22 THE AUSTRALASIAN COLLEGE OF DERMATOLOGISTS 2017 ASM MONDAY 8 MAY 2017

1100-1230 PLENARY 3 Room: Pyrmont Theatre Chair: A/Prof. S. Zagarella 1100 Prof. R. Rapini Rare infections 1115 Dr I. McCrossin Strongyloides in Australia - please don’t kill the patient 1125 Dr S. Rea The 2015-2016 syphilis outbreak of far North Queensland 1135 Dr N. Adler Nosocomial crusted scabies outbreaks at an Australian tertiary hospital: Infection prevention lessons learned from a small case series 1145 Dr A. Laino Systematic review of literature for treatment of chromoblastomycosis 1155 Dr A. Lara Rivero Tropical dermatoses not gone but forgotten? 1205 Dr A. Yazdabadi Cutaneous leishmaniasis, pearls from Persia 1215 Questions 1230 END OF SESSION

1230-1345 LUNCH IN THE TRADE EXHIBITION, HALL 1

1345-1515 PROFESSIONALISM AND ETHICS CONGRESS 1 Room: Pyrmont Theatre Chair: A/Prof. S. Zagarella 1345 Dr W. Lipworth Ethics in medicine 1405 Dr J. Jureidini Medical research: Selective reporting, publication bias, citation distortion, ghostwriting and endemic failure in pharmacovigilance 1425 Prof. L. Bero Big pharma. What have we learned from pharmaceutical industry documents? 1445 Dr B. Mintzes Who’s taking dermatologists out to dinner? 1505 Questions 1515 END OF SESSION

1515-1600 AFTERNOON TEA IN THE TRADE EXHIBITION, HALL 1

23 THE AUSTRALASIAN COLLEGE OF DERMATOLOGISTS 2017 ASM MONDAY 8 MAY 2017

1600-1645 PROFESSIONALISM AND ETHICS 1600-1730 REGISTRAR TEACHING SESSION CONGRESS 2 Room: Parkside 2 Room: Pyrmont Theatre Chair: Prof. A. Anstey Chair: Dr K. Chen 1600 A/Prof. S. Zagarella 1600 Dr S. Fosko Conflicts of interest in medical journals Lentigo maligna: Observations, challenges 1612 Mr T. Wills and advances Ethics talk 1620 Dr A. Marghoob 1624 Debate TADA: Dermoscopy simplified 1636 Questions 1640 Prof. R. Rapini 1645 END OF SESSION Journey in dermatology 1645-1730 ANNUAL GENERAL MEETING 1700 Prof. A. Anstey Room: Pyrmont Theatre How to get published 1720 Questions For Fellows and Associate Members of the College only 1730 END OF SESSION 1730 END OF SESSION

1730-1830 SPONSORED SYMPOSIUM 1730-1830 SPONSORED SYMPOSIUM Room: Pyrmont Theatre Room: Parkside 2 Chair: Dr J. Chan Dr A. Egeberg and Dr C-H. Hong  A/Prof. S. Smith and Dr J. Streimer Setting clear objectives for psoriasis The new normal – patient anxiety regarding treatment: Use of ixekizumab in clinical treatment success practice We are all aware patients are anxious their This symposium will focus on the clinical psoriasis treatment may not work as well efficacy and safety of ixekizumab in as they expect. But what about the issues moderate-to-severe plaques psoriasis, they may face when it does? And how does specifically in challenging situations. Dr this, and the fear their new treatment may Egeberg from Denmark and Dr Hong from stop working, affect their efforts to cope Canada will present case-based scenarios with this New Normal? Join us to discuss and lead an interactive discussion forum on the psychological impact of psoriasis and each case. management of patients with anxiety during 1830 END OF SESSION their treatment journey. 1830 END OF SESSION

social program 1800-2000 MEN’S AND LADIES TENNIS TOURNAMENT Centennial Parklands Sports Centre Anzac Parade and Lang Road, Moore Park Please meet at the ASM registration desk at 17:30 sharp.

24 THE AUSTRALASIAN COLLEGE OF DERMATOLOGISTS 2017 ASM TUESDAY 9 MAY 2017

0700-1500 REGISTRATION DESK OPEN

0730-0830 REGISTRARS’ FORUM 0730-0830 DERMATOLOGY HOSPITALISTS Room: Pyrmont Theatre Room: Parkside 2 Chair: Dr A. Lim Chair: A/Prof. P. Fernandez-Penas

0730 Dr F. Poon 0730 A/Prof . P. Fernandez-Penas Impact of neck lymphadenectomy on head and Presentation of dermatology neck cutaneous melanoma recurrence and hospitalists survival: A 10 year retrospective study 0737 Dr V. Tng 0731 Dr N. Adler General practice trainees’ clinical exposure to Recent advances in the dermatological procedures during training: An understanding and management of analysis from the registrar clinical encounters in severe cutaneous adverse reactions training study 0744 Dr J. Kim 0745 Dr G. Marshman Can neutrophilic eccrine hidradenitis be part of Rheumatology/dermatology MDT azathioprine hypersensitivity syndrome? 0755 Dr J. Wells 0751 Dr B. Choy Is the AQoL-8D a more sensitive instrument Update in cutaneous lymphomas than the skindex-16 for measuring impact of skin 0805 A/Prof. G. Cains conditions on quality of life? Managing hidradenitis suppurativa 0758 Dr P. Banan in a hospital MDT Morbihan’s disease in a patient with skin type IV and challenges of treatment 0815 Questions 0805 Dr R. Anforth 0830 END OF SESSION Treatment of disseminated actinic porokeratoses 0812 Dr J. Elakis Skin disease of penis and male genitalia is linked to atopy and circumcision: Aseload in a male genital dermatology clinic 0819 Dr L. Pitney Patch testing for cutaneous adverse drug reactions 0826 Questions 0830 END OF SESSION

0845-1015 NON-MELANOMA SKIN CANCER SYMPOSIUM 0845-1015 COSMETIC DERMATOLOGY FOR Room: Pyrmont Theatre GENERAL DERMATOLOGISTS Chair: Dr I. Hamann Room: Parkside 2 Chair: Dr M. Hunt 0845 Dr S. Fosko Targeted therapy and cutaneous squamous cell 0845 Dr M. Hunt carcinoma A 3-D approach to facial ageing 0855 Prof. M. Veness 0855 A/Prof. M. Freeman Ameliorating pigmentation and Update on merkel cell carcinoma telangiectasia in the skin 0905 Prof. M. Veness 0905 Dr A. Patel Sentinel lymph node biopsy in high risk SCC Levels of resurfacing 0915 Dr B. Yau 0915 Dr E. Dawes-Higgs Atypical fibroxanthoma/pleomorphic dermal sarcoma Dermal fillers at the Peter MacCallum Cancer Centre 2002-2016 0925 Dr A. Lim 0925 Dr R. Minocha High-speed low-pain micro-focused Nicotinamide for skin cancer chemoprevention: ultrasound tightening of the lower Effects on tumour immune infiltrates and face and neck melanoma biology 0935 Dr N. Wines 0935 A/Prof. P. Foley Botulinum toxin Structured expert consensus on actinic keratosis: 0945 Dr P. Sharma An up-to-date treatment algorithm Hair transplantation surgery: Where 0945 A/Prof. C. Palme are we now? Update on the surgical management of head and 0955 Dr P. Artemi neck perineural invasion Cosmeceutical options in 0955 Dr X. Yang dermatology practice Triple hedgehog pathway inhibition for advanced 1005 Dr M. Hunt basal cell carcinoma Beyond skin deep 1005 Questions 1010 Questions 1015 END OF SESSION 1015 END OF SESSION

25 THE AUSTRALASIAN COLLEGE OF DERMATOLOGISTS 2017 ASM TUESDAY 9 MAY 2017

1015-1100 MORNING TEA IN THE TRADE EXHIBITION, HALL 1

1100-1230 PLENARY 4 AND AWARDING OF PRIZES Room: Pyrmont Theatre Chair: Dr A. Miller 1100 Dr A. Marghoob How effective is dermoscopy in the early detection of melanoma? 1120 Prof. M. Ziman Liquid biopsies for diagnosis and prognosis of melanoma 1130 Dr D. Chung Ultrasound monitoring of lymph node metastasis in melanoma 1140 Dr P. Star Defining lentigo maligna and its margins and identifying predictors of recurrence: Correlation of clinical, dermatoscopic, confocal microscopy and histopathological data 1150 Dr S.J.E. Hwang Cutaneous adverse reactions to immunotherapies for metastatic melanoma 1200 Dr N. Maher Desmoplastic melanoma: A diagnostic difficulty 1210 Prof. D. Damian DPCP in the age of systemic immunotherapy 1220 Awarding of prizes 1230 END OF SESSION

1230-1345 LUNCH IN THE TRADE EXHIBITION, HALL 1

1345-1515 WHAT’S NEW IN JOURNALS 1345-1515 FREE PAPERS Room: Pyrmont Theatre Room: Parkside 2 Chair: Dr K. Chen Chair: Prof. G. Varigos 1345 Dr H. Fallah 1345 Prof. D. Murrell What’s new in medical dermatology Contributions of the independent learning 1405 Dr S. Lee program at University of New South Wales to dermatology registrar training 2006-2016 What’s new in surgical dermatology 1355 Prof. G. Varigos 1425 Dr K. Crotty 50 years ACD are we closer to a vaccine for What’s new in dermatopathology psoriasis? 1445 Dr L-C. Wong 1405 Prof. N. Haass What’s new in paediatric dermatology Cell cycle-tailored targeting of metastatic 1505 Questions melanoma: Challenges and opportunities 1515 END OF SESSION 1415 Dr P.S. Jones Case reports show benefit of an integrated approach to skin cancer treatment 1425 Dr P. Guitera Blue-grey pigmented lesions on trauma sites 1435 Dr A. Laino Iris freckling as a marker of melanoma risk 1445 Dr L. Abbott social program Surveillance by smartphone: Can a 1130 GOLF TOURNAMENT patient record a consultation without your The Lakes Golf Club consent? Corner King Street and Vernon 1455 Dr C. Gollins Avenue, Eastlakes A study of the number of female editors-in- chief of dermatology journals Please arrive at 1130 for a 1220 1505 Questions tee off. 1515 END OF SESSION

26 POSTER PRESENTATIONS

This year the posters will be displayed electronically in the ASM central feature in the trade E-POSTER SPONSOR exhibition. Posters can be viewed individually on computer terminals or delegates may access the e-Posters on their own device via the link http://acd2017asm.paperlessevents.com.au/ The link is also available in the menu bar of the ASM app.

1. Dr L. Abdel-Malek 20. Ms G. Bellemere Dermatology conferences and societies represented Characterisation of dry skin in vitro and in vivo in a on postage stamps paediatric population 2. Dr L. Abdel-Malek 21. Ms G. Bellemere Flagelate mushroom dermatitis: An uncommon Diaper dermatitis management: A global and emergency presentation innovative strategy for a new generation of skin care 3. Dr L. Abdel-Malek 22. Ms G. Bellemere Postage stamps and dermatology: Recognition of the Improving stretch mark pathophysiology knowledge dermatologist by specific in vitro models 4. Dr A. Adams 23. Ms G. Bellemere Incidental perineural invasion in NMSC: A In vitro models of infant skin to study molecular retrospective analysis of the QSkin study and a five mechanisms involved in paediatric atopic dermatitis year follow up in Queensland. 24. Ms G. Bellemere 5. Dr A. Adams In vivo and in vitro demonstration of efficacy of Nine primary melanomas in a young female patient specific skin care products for normal and dry baby and a review of the literature skin 6. Dr N. Adler 25. Ms G. Bellemere A novel clinical sign to aid in the diagnosis of Objective assessment of roughness of dry skin in a superficial basal cell carcinoma pediatric population 7. Dr N. Adler 26. Ms G. Bellemere Clinical and molecular characteristics and metastatic Studying the role of S. aureus and its biofilm in atopic pathways in patients with cutaneous melanoma dermatitis pathogenesis using in vitro 3D models 8. Dr N. Adler 27. Dr A. Bhullar Cutaneous adverse drug reactions and drug-induced A cross-sectional multicentre study to assess the liver injury: A retrospective cohort study quality of life in leprosy patients 9. Dr N. Adler 28. Dr T. Blake Successful treatment of pemphigus vulgaris with Desmoplastic trichoepithelioma - large case series, rituximab in a patient with severe vulvar involvement clinicopathology and management review 10. Dr N. Adler 29. Dr T. Blake Treatment of pemphigus vegetans with rituximab: A Updating dermatology medicine ingredient names in case report and review of the literature Australia – it’s happening right now! 11. Dr E. Anthony 30. Dr A. Blauvelt Acute generalised pustular psoriasis of pregnancy Efficacy of guselkumab within specific body regions 12. Dr E. Anthony in patients with moderate-to-severe plaque psoriasis: Pemphigus vulgaris: Therapeutic approach Results from the phase 3-VOYAGE 1 study 13. Dr C. Barker 31. Dr S. Bodapati Secukinumab treatment shows no evidence of Erythema nodosum and granulomatous mastitis: Case increased mycobacterium tuberculosis infections: study and discussion Findings from in vitro, in vivo and clinical investigations 32. Dr L. Buchanan 14. Dr T. Barrett A rare case of drug induced cutaneous lupus with Minocycline induced hyerpigmentation. A comparison tocilizumab for rheumatoid arthritis of Q-Switched Nd:YAG laser and picosecond 33. Dr J. Bu alexandrite laser Acute graft-versus-host-disease mimicking EAC: An 15. Dr R. Barsoum atypical cutaneous presentation Relationship between melanocytic naevi (MN) 34. Dr J. Bui acquired during childhood and adult MN count and Escherichia coli septicaemia induced purpura melanoma risk fulminans 16. Dr K. Beem 35. Dr J. Bui A case of dermal non-necrotising granulomatous Malignant melanoma and men’s health: The unspoken disease link 17. Dr K. Beem 36. Dr J. Bui Case series: Tinea incognito Topical glyceryl trinitrate treatment in chronic 18. Ms G. Bellemere radiation dermatitis A multidisciplinary approach of neonate and newborn 37. Dr N. Burkhardt hygiene and skin care Absolute and relative PASI over 1 year of treatment 19. Ms G. Bellemere with ixekizumab (IXE): Descriptive analysis in patients A natural cosmetic active ingredient dedicated to the with moderate-to-severe plaque psoriasis needs of pregnant woman’s skin

27 38. Dr N. Burkhardt 49. Miss S. Chap Efficacy and safety of ixekizumab (IXE) compared to Treatment of cutaneous kaposi sarcoma with topical ustekinumab (UST) in patients with moderate-to-severe timolol plaque psoriasis: A randomised head-to-head trial 50. Dr O. Charlton 39. Dr N. Burkhardt Leprosy: An ancient disease that still threatens global Indirect comparison of ixekizumab (IXE) and health secukinumab (SEC) using matched-adjusted indirect 51. Dr H.M. Cheng comparisons (MAIC) Retrospective review of lichen planus pigmentosus 40. Dr N. Burkhardt (LPP) and ashy dermatosis (AD) – Risk factors, Ixekizumab (IXE) treatment enables rapid clinicopathologic features, and treatment outcomes improvements in health-related quality of life (HRQoL) 52. Dr M. Cho and itch: Results from UNCOVER-2 and UNCOVER-3 Plantar keratoderma associated with developmental 41. Dr M.A. Castrillon delay, intellectual impairment and abnormal facial A case report of lupus erythematosus profundus features. A possible new gene (FOXP1) association 42. Dr J. Cather 53. Dr H. Collgros ≥156-week apremilast safety and tolerability in patients In vivo reflectance confocal microscopy on the with moderate to severe psoriasis and cardiometabolic lip: From normal to sun damaged skin and non- comorbidities: ESTEEM pooled analysis melanocytic skin cancer 43. Dr K. Chakradeo 54. Miss C. Cox Atypical cellulitis in transplant recipients: A case Efficacy of home-based chemo-wraps of topical report and review of the literature 5-fluorouracil for disseminated superficial actinic 44. Dr K. Chakradeo porokeratosis compared to ablative erbium laser: Eruptive seborrheic keratoses in a patient with intra- Comparative case study abdominal malignancy: Sign of leser–trélat 55. Dr W. Cranwell 45. Dr M.Y.L. Chan The role of sunscreen and facial skin care products in Muscle, skin or both? Concurrent psoriasis and frontal fibrosing alopecia dermatomyositis with pembrolizumab treatment of 56. Dr J. Crowley metastatic melanoma ≥156-week apremilast safety in psoriasis and psoriatic 46. Dr M.Y.L. Chan arthritis patients: Pooled analysis of the ESTEEM and Red and sore in a rare patient PALACE phase 3 trials 47. Dr S-L. Chan 57. Dr K. Darch A case of bullous pemphigoid in a young adult Investigating the correlation between ion channels and receptors that detect irritants, and itchy, 48. Miss S. Chap inflammatory skin conditions Profiling cysteine protease activity in atopic dermatitis

FROM 3 RD JULY 2017 THE

*PFP IS CHANGING

Visit the Celgene trade display for further information

*PFP = Product Familiarisation Program. PBS Information: This product is not listed on the PBS. Before prescribing Otezla (apremilast) please refer to the full Product Information (PI) which is available on request from Celgene by calling 1800 235 4363 and from the Celgene trade display. Further information is available from Celgene Pty Ltd ABN 42 118 998 771. Level 15, 60 City Road, Southbank VIC 3006, Australia. Tel 1800 CELGENE (1800 235 4363) www.celgene.com.au ®Registered Trademark. EMVOTZ0138 Date Prepared: April 2017.

28 58. Dr J. Davey 78. Dr A. Gin Life on the beach: The knowledge, behaviours and Coxsackievirus A6 associated with eczema attitudes of Australian surf lifesavers towards sun exacerbation in children protection 79. Cl. Prof. C-L. Goh 59. Dr S. Dawood Management of post-acne scars in Asians - need for a The U.K. skin cancer ‘two-week rule’ referral system: paradigm shift? Audit to ascertain appropriate referrals at our 80. Dr C. Gollins institution A case of bladder calculi in non-herlitz junctional 60. Dr N. De Rosa epidermolysis bullosa Dermatological disease in heart and lung transplant 81. Dr A. Gottlieb recipients: A cross-sectional and prospective study Clinical response and minimal disease activity with 61. Dr N. De Rosa the physician global assessment and body surface Skin cancer incidence and risk factors in Australian area tool: Apremilast ESTEEM analysis heart and lung transplant recipients: A single-centre 82. Dr S. Hall retrospective study Secukinumab provides sustained improvement in 62. Dr J. Deen psoriatic arthritis in both anti-TNF-naïve and anti-TNF Extrafacial granuloma faciale exposed patients 63. Dr J. Deen 83. Dr M. Hamid Severe, malignant acanthosis nigricans associated Calciphylaxis: Clinical presentation, causes and with adenocarcinoma of the endometrium treatment, with case series 64. Dr P. Dickison 84. Dr M. Hamid Cardiovascular risk in psoriasis patients The evolution and workflow of the Princess Alexandra 65. Dr P. Dickison Hospitals’ teledermatology service, and an interesting Medical student perceptions of dermatology teaching: case series A focus group study 85. Ms E. Hao 66. Dr P. Dickison Systematic review of neonatal cutaneous langerhan Professional perceptions of dermatology teaching: A cell histiocytosis and metaanlysis of risk of focus group study progression to systemic disease 67. Dr P. Dickison 86. Dr V. Harris Psoriasis patients’ knowledge of comorbidities Assessment of sun-protective attitudes and behaviours of parents and the impact on their children 68. Dr B. Doolan Management of primary cutaneous melanoma: A 87. Dr V. Harris retrospective audit of 349 cases and literature review First case report of ustekinumab and botulinum toxin A of current clinical guidelines injections in a patient 69. Dr B. Doolan 88. Dr V. Harris Tinea capitis caused by trichophyton tonsurans in Update: Autoimmune side effects of ipiliumumab and tropical Africa: A review of the scientific literature pembrolizumab in metastatic melanoma. Case study of patient with hypophysitis, pneumonitis, colitis, 70. Dr J. Elakis vitiligo Barriers to JMO participation in pressure injury prevention and management 89. Dr N. Huang A case of granulomatous cheilitis in miescher- 71. Dr G. Farrah melkersson-rosenthal syndrome A case of disseminated granuloma annulare associated with dermatomyositis 90. Dr S.J.E. Hwang Cutaneous toxicities of anti-programmed death (anti- 72. Dr L. Farrugia PD-1) antibodies in patients with advanced solid organ Evaluation of the influence of family and friends, and tumours the internet on patient perceptions of long-term topical corticosteroid use 91. Dr S.J.E. Hwang Difference in skin toxicities observed in patients 73. A/Prof. P. Foley with metastatic melanoma treated with combined Dupilumab with concomitant topical corticosteroids in pembrolizumab and ipilimumab vs pembrolizumab moderate-to-severe atopic dermatitis: A randomised, alone placebo-controlled phase 3 clinical trial (CHRONOS) 92. Ms E. Janz-Robinson 74. A/Prof. P. Foley Is it really vitiligo? Secukinumab shows significant efficacy in difficult-to- treat palmoplantar psoriasis: 1.5 year data from the 93. Dr T. Jeffery GESTURE study Lichenified papules – an unusual cutaneous presentation of metastatic breast cancer 75. Dr J. Frew A systematic review and critical evaluation of reported 94. Dr H. Jibreal sequence variants in hidradenitis suppurativa/acne Fractionated laser and radiofrequency treatments inversa using ACMG standards and guidelines combined with low-dose isotretinoin for the concurrent treatment of active acne and acne scarring 76. Dr S. Gabizon Pyogenic granuloma like kaposi sarcoma 95. Dr J. Johnston A case of adult onset linear scleroderma, en coup 77. Dr L. Ge sabre variant responsive to methotrexate monon- A case of anhidrosis and widespread vitiligo- treatment: A review of treatment options like depigmentation with metastatic melanoma immunotherapy

29 96. Dr J. Johnston 115. Mr E. Mate The correlation of sebaceous hyperplasia and colonic Secukinumab demonstrates sustained high efficacy polyposis: An observational study and a tolerable safety profile in moderate-to-severe 97. Dr P.S. Jones psoriasis patients through 4 years of treatment Vitiligo surgery: A faster method of suction blistering 116. Mr E. Mate using the celluTome device Secukinumab is efficacious in clearing moderate- 98. Dr P. Kadam to-severe scalp psoriasis: 12 week results of a Hydroxyurea induced squamous dysplasia randomised phase IIIb study 99. Dr P. Kadam 117. Dr P. McDonald Systemic cutaneous anaplastic large t-cell lymphoma A paradoxical reaction in a mycobacterium ulcerans infection 100. Dr J. Kim Multiple glomus tumours: A rare dermatological 118. Dr R. Meani presentation Incidence of vulval squamous cell carcinoma in women with vulval lichen sclerosus in an Australian 101. Dr M. Kim tertiary referral centre Sirolimus-associated scrotal lymphedema and secondary development of lymphangiomatosis: 119. Dr A. Mulcahy Successful treatment with shave excision and A curious case of bed bugs and a lesson of referral cauterization caution 102. Dr J. Korbl 120. Dr A. Mulcahy “Why don’t they ever call?”: Critical diagnoses in Dermatological conditions in haematology patients: dermatopathology Data from combined haematology/dermatology clinic 103. Miss E. Kozera 121. Dr A. Mulcahy Patient and practitioner satisfaction with tele- Suggested skin cancer screening protocol for chronic dermatology including Australia’s indigenous lymphocytic leukaemia patients population 122. Prof. D. Murrell 104. Dr N. Laidler A pilot study of the efficacy of a bruton’s tyrosine Acute autoimmune hepatitis secondary to ipilimumab kinase inhibitor in the treatment of dogs with in metastatic melanoma pemphigus foliaceus 105. Dr A. Laino 123. Dr N. Nagodavithana Cutaneous adverse reactions following alemtuzumab Nation wide survey on the use of photodynamic therapy for multiple sclerosis therapy among Australian dermatologists 106. Dr A. Lee 124. Dr P. Nash Successful use of ibrutinib to control paraneoplastic Secukinumab provides rapid and sustained reductions pemphigus in a patient with paraneoplastic in dactylitis, enthesitis, and nail psoriasis in patients autoimmune multiorgan syndrome and chronic with psoriatic arthritis (PsA) lymphocytic leukaemia 125. Dr Y. Nguyen 107. Dr S. Lee A case of cutaneous malakoplakia in a patient with Recalcitrant ulcers associated with SAE-positive chronic graft-versus-host disease dermatomyositis treated with surgery followed by 126. Dr Y. Nguyen intravenous immunoglobulin A case series of 16 patients with oestrogen 108. Dr N. Ling hypersensitivity vulvitis treated with cyproterone Granulomatous mycosis fungoides: A difficult acetate diagnosis 127. Dr Y. Nguyen 109. Dr R. Liu Management of chronic vulvovaginal candidiasis: A Nivolumab induced subacute cutaneous lupus long term retrospective study erythematosus 128. Dr Y. Nguyen 110. Dr H. Lolatgis Poor quality of life in patients with chronic Direct and indirect costs of adult atopic dermatitis in vulvovaginal candidiasis: A before-after study on the an inpatient and outpatient setting impact of oral fluconazole therapy 111. Dr D. Maor 129. Mr K. Nørremark A case of acquired epidermodysplasia verruciformis in Innovation in delivery of a topical combination a renal transplant recipient clearing with multimodal treatment (enstilar®) for psoriasis vulgaris treatment including gardasil vaccination 130. Dr D. Norris 112. Dr D. Maor Biologics and dermatology life quality index (DLQI) in Melanoma in a cohort of organ transplant recipients: the Australasian psoriasis population Experience from a dedicated transplant dermatology 131. Dr P. Peters clinic in Victoria Combined dermatology/stomal clinic: A 113. Dr D. Maor new multidisciplinary clinic Recalcitrant hyperkeratotic warts in a renal 132. Dr C. Pham transplant recipient clearing with cessation of Granular parakeratosis in adult female secondary to immunosuppression exposure of benzalkonium chloride laundry rinse 114. Dr N. Martin 133. Dr V. Pilcher EASI-75 interpretation from a patient perspective – a The development of generalised granuloma annulare phase 2b post-hoc analysis of dupilumab in adults during treatment for palmoplantar psoriasis with with moderate-to-severe atopic dermatitis ustekinumab

30 134. Dr V. Pilcher 156. Dr V. Snaidr The development of vitiligo while receiving Pigmented epithelioid melanocytoma: Case report and ustekinumab therapy for chronic plaque psoriasis - a update on the nomenclature of paediatric melanocytic case series tumours 135. Dr M. Robinson 157. Dr P. Sobarun Large brown scale: DDx and Ix. A case report of X A rare acral lesion with parallel-ridge pattern on linked ichthyosis and review of literature on treatment dermoscopy options 158. Dr F. Spada 136. Dr R. Saunderson Is there a problem with parabens? Teledermatology – how accurate is it? 159. Dr F. Spada 137. Dr A. Schauer Providing intense moisturisation for extremely dry skin Ipilimumab-induced Stevens Johnson Syndrome 160. Dr L. Spelman 138. Dr A. Schauer Secukinumab 300mgs is more efficacious than Stretching scleromxyoedema treatment with IVIG ustekinumab 90mgs: Analysis of patients with body 139. Mr A. Scott weights over 100kg from the CLEAR study A tattoo pigment reaction in a patient with metastatic 161. Dr P. Star melanoma treated with dabrafenib and trametinib Immunotherapy-induced pustular psoriasis in a patient 140. Dr J-A. See with metastatic melanoma High patient satisfaction with daylight-activated methyl 162. Dr P. Stevenson aminolevulinate cream in the treatment of multiple Multiple pilomatrixomas in a paediatric patient leading actinic keratoses: A non-interventional study in Australia to a diagnosis of familial adenomatous polyposis 141. Dr E. Shao 163. Dr P. Stevenson Botox and axillary hyperhidrosis: A retrospective study Obtaining patients’ informed consent for clinical at a dermatology centre photographs: An audit of dermatology registrars’ 142. Dr E. Shao practices at a tertiary hospital Erythema dyschromicum perstans and the betel nut 164. Dr P. Stevenson 143. Dr E. Shao Treating severe plaque psoriasis in a paediatric Lepromatous leprosy: Case based clinico-histologic patient with etanercept discussion 165. Dr T. Stewart 144. Dr E. Shao A cross-sectional study of psychological stress and Pachydermoperiostosis: A rare case study skin symptoms in Australian university students 145. Dr E. Shao 166. Ms J. Stone Panniculitis secondary to vancomycin Comparison between parent versus clinician assessment of disease severity in childhood atopic 146. Dr E. Shao dermatitis Tattoo reactions: The experience of a dermatology centre offering tattoo removal services 167. Dr J. Sullivan Secukinumab in pregnancy: Outcomes from the global 147. Dr S. Sharma safety database Schnitzler syndrome: A rare cause of chronic recalcitrant urticaria 168. Dr J. Sullivan Secukinumab shows significant efficacy in nail 148. Mr J. Shen psoriasis: Week 32 results from the TRANSFIGURE Management of cutaneous adverse events associated study with daclizumab treatment in multiple sclerosis patients 169. Dr A. Swarbrick Cutaneous amyloidosis: Several illustrative cases 149. Ms E. Sideris Patients’ sun practices, perceptions of skin cancer and 170. Dr A. Swarbrick their risk of skin cancer in rural Australia Toxic shock syndrome: Illustrating the importance of history and examination 150. Miss E. Sim Fish tank granuloma in Chinese restaurant chefs in 171. Dr J-M. Tan Victoria – an occupational hazard The prevalence of BRAF and NRAS in dermoscopic subtypes of acquired naevi 151. Prof. R. Sinclair Secukinumab provides faster, more sustained relief 172. Dr Y. Tanaka from psoriasis-related pain, itching and scaling than Cytocidal effect of water-filtered broad-spectrum near- ustekinumab in subjects with moderate-to-severe infrared on cancer cells plaque psoriasis 173. Dr Y. Tanaka 152. Dr A. Smith The necessity of solar near-infrared protection shown Global dermatology - a trainee’s perspective through gene expression changes 153. Dr S. Smithson 174. Dr Y. Tanaka Consensus statement for the treatment of infantile Type I collagen production stimulation of water- haemangiomas with propranolol filtered near-infrared shown through gene expression changes in a 3-dimensional human epidermal tissue 154. Dr S. Smithson model The use of IVIg for refractory bullous pemphigoid secondary to pembrolizumab: A case report 175. Dr C. Tancharoen An audit of inpatient dermatology admissions: 155. Dr S. Smithson Management of hyperglycaemia in oral glucocorticoid The use of mycophenolate mofetil to treat mid dermal use elastolysis: A case report

31 176. Dr S. Taylor 199. Mr C. Wang Efficacy and safety of topical dapsone gel .5%7 for Acute localised exanthematous pustulosis secondary treatment of acne vulgaris by fitzpatrick skin type to pembrolizumab 177. Dr C. Thomas 200. Dr E. Wee Non-melanoma skin cancer and quality of life in an An annular purpuric eruption secondary to a Australian population lymphocytic vasculitis with mixed features of livedoid TALTZ®: For moderate-to-severe plaque 178. Dr C. Thomas vasculitis and lymphocytic thrombophilic arteritis NEW psoriasis in adult patients who are candidates Stronglyloides hyperinfection syndrome complicating 201. Dr E. Wee for systemic therapy or phototherapy.1 corticosteroid therapy for pemphigus vulgaris Australian dermatology trainee opinions on skin 179. Dr S. Thomas of colour education: Does it reflect the changing Involution of selective melanocytic lesions in a 79 year- demographics of our population? old male with metastatic melanoma on immunotherapy 202. Dr J. Witherspoon 180. Dr J. Tiing The management of dysplastic naevi: A survey of the An audit of pigmentation disorders due to infection fellows of The Australasian College of Dermatologists seen at a private dermatology clinic in Western 203. Dr G.N. Wong Australia Case report: Secondary syphilis masquerading as tinea corporis AIMING FOR 181. Dr J. Tiing Epidermodysplasia verruciformis resembling pityriasis 204. Dr V. Wong versicolor Congenital erosive and vesicular dermatosis with 182. Dr L. Timoney reticulated supple scarring: A report of two new cases CLEAR A case of angiolymphoid hyperplasia with 205. Dr V. Wong eosinophilia. Narrowband ultraviolet B phototherapy in recalcitrant 183. Dr L. Timoney vulval psoriasis: A local treatment protocol and pilot study A rare case of primary rhabdoid malignant melanoma 206. Dr A. Wu TOUCHABLE Proportion of melanoma excisions performed by 184. Dr L. Timoney 1–8† Amelanotic lentigo maligna melanoma: Beware the different specialties in Australia wolf in sheep’s clothing 207. Dr C. Wyatt 185. Dr L. Timoney Nodules in the newborn- 3 cases of congenital self- SKIN. Myxoid dermatofibrosarcoma protuberans with healing histiocytosis fibrosarcomatous features 208. Dr J. Xu † 186. Dr R. Toholka Melanomas in prepubescent children versus Up to 41% of patients achieved PASI 100 at Week 12 in UNCOVER Erythema induratum, a classic case of a tuberculid pubescent children in the Western Australian reaction melanoma advisory service phase III trials; 58% of Week 12 responders (sPGA 0/1; pooled analysis 187. Dr R. Toholka 209. Dr J. Xu of UNCOVER-1 and UNCOVER-2) maintained or achieved PASI 100 Primary osteoma cutis Paediatric melanomas: Western Australian melanoma advisory service experience by Week 60; improvement at Week 12 vs baseline in areas associated 188. Dr E. Tong Perils and pearls of purchasing sun protection on the 210. Dr A. Yang with touch avoidance.1–8 internet DRESS induced by a weight loss protein shake - the misfortune of good intentions 189. Dr M.C. Tran Flagellate erythema: Review of causes, with 211. Dr X. Yang dramatic case presentation in young female with Intertriginous planar xanthoma secondary to dyslipidaemia in an infant dermatomyositis AT WEEK 12 OF PATIENTS OF PATIENTS OF PATIENTS 190. Dr N. Valecha 212. Dr F. Yap ACHIEVED ACHIEVED ACHIEVED A rare case of lues maligna with ocular involvement (UNCOVER-2 90% 71% 41% Non-cultured melanocyte transplantation for 1,2 1,2 1,2 treatment of stable leucoderma: Experiences of an after immune reconstitution syndrome phase III trial): Australian centre 213. Dr F. Yap PASI 75 PASI 90 PASI 100 191. Prof. G. Varigos Capecitabine exacerbates psoriasis in colon cancer Essential for next 50 years dermatology clinical patients. A case report research registries at the bedside BIOGRID 214. Dr F. Yap 192. Dr D. Vekic Erythema nodosum leprosum (ENL) with sub-acute SAPHO syndrome associated with hidradenitis mono-neuritis multiplex: A rare presentation and suppurativa and pyoderma gangrenosum successfully challenging disease to manage PBS INFORMATION: Authority required. For the treatment of severe chronic plaque psoriasis. treated with adalimumab and methotrexate 215. Dr F. Yap Refer to PBS Schedule for full Authority information. 193. Dr D. Vekic Perianal pseudoverrucous papules and nodules in The expanding spectrum of autoinflammatory hirschprung’s disease: Rapid resolution with oral syndromes related to hidradenitis suppurativa loperamide Please refer to the full Product Information before prescribing. Product Information can be accessed 194. Dr M. Vu 216. Dr A. Yazdabadi at www.lilly.com.au/en/products/ or on request by calling 1800 454 559. Artificial intelligence, predicting outcomes in Brooke-spiegler syndrome: The impact of a rare disease ® ® photodynamic therapy TALTZ Minimum Product Information. INDICATIONS – TALTZ is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic 195. Dr M. Vu therapy or phototherapy. CONTRAINDICATIONS – Serious hypersensitivity to ixekizumab or any of the excipients. PRECAUTIONS – Chronic or active infections, do not administer in patients Hypertrophic lichenoid reactions secondary to anti- 217. Prof. G. Yosipovitch with active tuberculosis; hypersensitivity – discontinue treatment immediately if a serious hypersensitivity reaction occurs; inflammatory bowel disease – exercise caution; immunisations – PD-1 therapy Validation of the peak pruritus numerical rating scale: do not use with live vaccines; Use in Pregnancy Category C. ADVERSE EFFECTS Clinical Trials Experience – Very Common (≥10%) injection site reactions (including erythema and pain), Results from clinical studies of dupilumab in adults infection (including nasopharyngitis and upper respiratory tract infection), Common (≥1 and <10%) nausea, oropharyngeal pain, tinea infections, grade 1 or 2 neutropenia. DOSAGE AND 196. Dr M. Vu with moderate-to-severe atopic dermatitis ADMINISTRATION – Dosage: Two 80 mg by subcutaneous injection at Week 0, followed by one 80 mg injection every 2 weeks at Weeks 2, 4, 6, 8, 10 and 12, then one 80 mg injection Lichen planus following influenza immunisation every 4 weeks. Elderly Patients (≥65 years): Dose adjustment not required. Renal Impairment or Hepatic Impairment: No dosage recommendations. Administration: Subcutaneous injection, 218. Dr C. Zhao avoid area showing psoriasis if possible. Single-use in one patient only. TALTZ® contains no antimicrobial preservative, discard any residue product. Based on PI last amended 5 April 2017. 197. Dr M. Vu Anti-programmed cell death 1’s effects on cutaneous ® Oral tofacitinib - a promising treatment in atopic References: 1. TALTZ (ixekizumab) Approved Product Information, 5 April 2017. 2. Griffiths C et al. Lancet 2015;386:541–551. 3. Gordon K et al (supplementary appendix). N Engl J Med squamous cell carcinoma in patients with metastatic 2016;375:345–356. 4. Gupta MA et al. Cutis 1998;61:339–342. 5. Bleakman AP et al. Presented at: 23rd World Congress of Dermatology; June 8–13, 2015; Vancouver, Canada. 6. Reich K dermatitis, alopecia areata and vitiligo melanoma et al. J Am Acad Dermatol 2016;74(5) (suppl 1);AB253. 7. Menter A et al. J Am Acad Dermatol 2016;74(5) (suppl 1);AB253. 8. Dennehy EB et al. J Drug Dermatol 2016;15(8):958–961. 198. Dr T. Wain 219. Dr C. Zhao Abbreviations: PASI, Psoriasis Area Severity Index; sPGA, static Physician’s Global Assessment. Methotrexate in primary cutaneous t-cell lymphoma Melanocytic lesion evolution patterns with targeted TALTZ® is a registered trademark of Eli Lilly and Company. Eli Lilly Australia Pty Ltd. 112 Wharf Road, West Ryde NSW 2114, Australia. therapies and immunotherapies for advanced ABN 39 000 233 992. Medical information: 1800 454 559. Date of preparation: April 2017. PP-IX-AU0235. ELT0140. 32 metastatic melanoma

ELT0140_ACD_Trade_Exhibition_Program_Ad_AW05.indd 1 20/04/2017 4:01 pm TALTZ®:TALTZ®: For For moderate-to-severe moderate-to-severe plaque plaque NEWNEW psoriasispsoriasis in adultin adult patients patients who who are are candidates candidates for forsystemic systemic therapy therapy or phototherapy.or phototherapy.1 1 AIMING AIMING FOR FOR CLEARCLEAR TOUCHABLETOUCHABLE SKIN.SKIN.1–81–8† † † Up† Up to to41% 41% of ofpatients patients achieved achieved PASI PASI 100 100 at atWeek Week 12 12 in UNCOVERin UNCOVER phasephase III trials;III trials; 58% 58% of ofWeek Week 12 12 responders responders (sPGA (sPGA 0/1; 0/1; pooled pooled analysis analysis of ofUNCOVER-1 UNCOVER-1 and and UNCOVER-2) UNCOVER-2) maintained maintained or orachieved achieved PASI PASI 100 100 by byWeek Week 60; 60; improvement improvement at atWeek Week 12 12 vs vsbaseline baseline in areasin areas associated associated withwith touch touch avoidance. avoidance.1–81–8

ATAT WEEK WEEK 12 12 OF OFPATIENTS PATIENTS OF OFPATIENTS PATIENTS OF OFPATIENTS PATIENTS (UNCOVER-2(UNCOVER-2 9090%%ACHIEVEDACHIEVED 7171%%ACHIEVEDACHIEVED 4141%%ACHIEVEDACHIEVED 1,2 1,2 1,2 1,2 1,2 1,2 phasephase III IIItrial): trial): PASIPASI 75 75 PASIPASI 90 90 PASIPASI 100 100

PBSPBS INFORMATION: INFORMATION: Authority Authority required. required. For For the the treatment treatment of ofsevere severe chronic chronic plaque plaque psoriasis. psoriasis. ReferRefer to toPBS PBS Schedule Schedule for for full full Authority Authority information. information. PleasePlease refer refer to tothe the full full Product Product Information Information before before prescribing. prescribing. Product Product Information Information can can be be accessed accessed at atwww.lilly.com.au/en/products/ www.lilly.com.au/en/products/ or oron on request request by by calling calling 1800 1800 454 454 559. 559. TALTZTALTZ® Minimum® Minimum Product Product Information. Information. INDICATIONS INDICATIONS – TALTZ – TALTZ® is indicated® is indicated for the for treatmentthe treatment of adult of adult patients patients with withmoderate-to-severe moderate-to-severe plaque plaque psoriasis psoriasis who whoare candidatesare candidates for systemic for systemic therapytherapy or phototherapy. or phototherapy. CONTRAINDICATIONS CONTRAINDICATIONS – Serious – Serious hypersensitivity hypersensitivity to ixekizumab to ixekizumab or any or ofany the of excipients.the excipients. PRECAUTIONS PRECAUTIONS – Chronic – Chronic or active or active infections, infections, do not do administernot administer in patients in patients with withactive active tuberculosis; tuberculosis; hypersensitivity hypersensitivity – discontinue – discontinue treatment treatment immediately immediately if a seriousif a serious hypersensitivity hypersensitivity reaction reaction occurs; occurs; inflammatory inflammatory bowel bowel disease disease – exercise – exercise caution; caution; immunisations immunisations – – do notdo usenot withuse withlive vaccines;live vaccines; Use Usein Pregnancy in Pregnancy Category Category C. ADVERSE C. ADVERSE EFFECTS EFFECTS Clinical Clinical Trials Trials Experience Experience – Very – Very Common Common (≥10%) (≥10%) injection injection site reactionssite reactions (including (including erythema erythema and andpain), pain), infectioninfection (including (including nasopharyngitis nasopharyngitis and andupper upper respiratory respiratory tract tract infection), infection), Common Common (≥1 and(≥1 and<10%) <10%) nausea, nausea, oropharyngeal oropharyngeal pain, pain, tinea tinea infections, infections, grade grade 1 or 12 orneutropenia. 2 neutropenia. DOSAGE DOSAGE AND AND ADMINISTRATIONADMINISTRATION – Dosage: – Dosage: Two Two80 mg 80 bymg subcutaneous by subcutaneous injection injection at Week at Week 0, followed 0, followed by one by one80 mg 80 injectionmg injection every every 2 weeks 2 weeks at Weeks at Weeks 2, 4, 2, 6, 4, 8, 6, 10 8, and 10 and12, then12, then one one80 mg 80 injectionmg injection everyevery 4 weeks. 4 weeks. Elderly Elderly Patients Patients (≥65 ( ≥years):65 years): Dose Dose adjustment adjustment not required.not required. Renal Renal Impairment Impairment or Hepatic or Hepatic Impairment: Impairment: No dosage No dosage recommendations. recommendations. Administration: Administration: Subcutaneous Subcutaneous injection, injection, avoidavoid area area showing showing psoriasis psoriasis if possible. if possible. Single-use Single-use in one in onepatient patient only. only. TALTZ TALTZ® contains® contains no antimicrobial no antimicrobial preservative, preservative, discard discard any residueany residue product. product. Based Based on PI on last PI amendedlast amended 5 April 5 April 2017. 2017. References:References: 1. T ALTZ1. TALTZ® (ixekizumab)® (ixekizumab) Approved Approved Product Product Information, Information, 5 April 5 April 2017 2017. 2. Griffiths. 2. Griffiths C et al.C et Lancet al. Lancet 2015;386:541–551. 2015;386:541–551. 3. Gordon 3. Gordon K et Kal et(supplementary al (supplementary appendix). appendix). N Engl N EnglJ Med J Med 2016;375:345–356.2016;375:345–356. 4. Gupta 4. Gupta MA etMA al. et Cutis al. Cutis 1998;61:339–342. 1998;61:339–342. 5. Bleakman 5. Bleakman AP et AP al. et Presented al. Presented at: 23rd at: 23rd World World Congress Congress of Dermatology; of Dermatology; June June 8–13, 8–13, 2015; 2015; Vancouver, Vancouver, Canada. Canada. 6. Reich 6. Reich K K et al.et J al.Am J AcadAm Acad Dermatol Dermatol 2016;74(5) 2016;74(5) (suppl (suppl 1);AB253. 1);AB253. 7. Menter 7. Menter A et Aal. et J al.Am J AcadAm Acad Dermatol Dermatol 2016;74(5) 2016;74(5) (suppl (suppl 1);AB253. 1);AB253. 8. Dennehy 8. Dennehy EB et EB al. et J al.Drug J Drug Dermatol Dermatol 2016;15(8):958–961. 2016;15(8):958–961. Abbreviations:Abbreviations: PASI, PASI, Psoriasis Psoriasis Area Area Severity Severity Index; Index; sPGA, sPGA, static static Physician’s Physician’s Global Global Assessment. Assessment. TALTZTALTZ® is ®a registeredis a registered trademark trademark of Eli of Lilly Eli Lillyand andCompany. Company. Eli Lilly Eli LillyAustralia Australia Pty Ltd.Pty Ltd.112 112Wharf Wharf Road, Road, West West Ryde Ryde NSW NSW 2114, 2114, Australia. Australia. ABNABN 39 000 39 000233 233992. 992. Medical Medical information: information: 1800 1800 454 454559. 559. Date Date of preparation: of preparation: April April 2017. 2017. PP-IX-AU0235 PP-IX-AU0235. ELT0140.. ELT0140. 33

ELT0140_ACD_Trade_Exhibition_Program_Ad_AW05.inddELT0140_ACD_Trade_Exhibition_Program_Ad_AW05.indd 1 1 20/04/201720/04/2017 4:01 4:01pm pm FLOOR PLAN OF THE TRADE EXHBITION AREA

HALL 1 FLOOR PLAN

34 LOOKS CAN BE DECEIVING IN ATOPIC DERMATITIS To find out more please visit us at the Sanofi Genzyme stand

Sanofi-aventis Australia pty ltd trading as Sanofi Genzyme, ABN 31 008 558 807. Talavera Corporate Centre, Building D 12-24 Talavera Road, Macquarie Park, NSW 2113. www.sanofigenzyme.com.au. GZANZ.DUP.17.04.0058a. Date of preparation April 2017. SAG0096.

SAG0096_ACD Program Ad_V1.indd 1 19/04/2017 3:11 PM Stand Stand Company Number Company Number AbbVie 81-86 HEINE Australia 1-2 Advanced Cosmeceuticals 93-95 High Tech Laser Australia 33 Allergan 41-44 Ionia Medical 91 AllergEnd and Orbis Australasia 89 Janssen-Cilag 65-70 Aspen Pharmacare 13 Johnson & Johnson 10-11 Aussie Medi Tech 110 Key Pharmaceuticals 97 Australasian Blistering Diseases Foundation 22 K-Laser Australia 109 Australasian College of Dermatologists 111-114 KOSmedical 109 Australia Alopecia Areata Foundation (AAAF) 117 Kossard Dermatopathologists 46 Australia and New Zealand Melanoma Trials Group 19 La Roche-Posay (L'OREAL) 58 & 60 Australian Dermatology Equipment 102 LEO Pharma 5-8 Australian Gorlin Syndrome Support Group 118 Lumenis Australia 35-36 Australian Ultra Violet Services 23 Cryomed 99 Avita Medical 96 CustomMed Compounding Pharmacy 47 Bayer Australia 39 Cutera Australia 80 BIODERMA (CDF) 88 Cynosure 40 Bio-Oil 12 Macquarie Medical Systems 78 BOQ Specialist 14 Marne Medical 29 BrightSky Australia 94 Medifit Design & Construct 4 Menarini Australia 32 Celgene 61-64 Merz Australia 24-25 COMPOUNDED Pty Ltd 92 MSD 27 Critical Group 26 Mylan 98 Cryomed Aesthetics 99 CustomMed Compounding Pharmacy 47 NeoStrata 16 Nevus Support Australia Inc 120 Cutera Australia 80 Nice Pak Products 90 Cynosure 40 Novartis Pharmaceuticals 49-52 DEBRA Australia 116 Oraderm Pharmaceuticals 34 Dermocosmetica 87 Pierre Fabre (Avène) 37-38 Dorevitch Pathology 45 Propaira 30 Douglass Hanly Moir Pathology 121 Psoriasis Australia Inc 21 Eczema Association of Australasia Inc 119 Sanofi Genzyme 57-59 Ego Pharmaceuticals 103-106 Scanmedics (Paragon Care) 48 Eli Lilly Australia 53-56 EndyMed Medical 15 Skin & Cancer Foundation Inc 18 Expanscience Laboratories - Mustela 107 Sun Pharma 100-101 Firstcheck 28 Syneron Candela 31 Galderma Australia 71-76 The Australasian College of Dermatologists 111-114 Genie Solutions 9 The Skin Hospital and Skin & Cancer Foundation Australia 17 GlaxoSmithKline Australia (GSK) 77-79 Vitiligo Association of Australia (VAA) 20 Hands to Hold Ltd 115 Vorotek 108 35 ACKNOWLEDGEMENTS The Australasian College of Dermatologists kindly acknowledges the generous support of the following sponsors in assisting with the Annual Scientific Meeting:

Platinum Sponsors

Gold Sponsors

Silver Sponsors

AUSTRALASIAN COLLEGE OF DERMATOLOGISTS PO Box 3785, RHODES NSW 2138, Australia Other Sponsors T +61 2 8765 0242 or 1300 361 821 (within Australia only) F +61 2 9736 2194 E [email protected] W https://www.dermcoll.edu.au

www.acdasm2017.com